

PCT

WORLD INTELLECT  
Int

INTERNATIONAL APPLICATION PUBLISHED

WO 9603385A1

(51) International Patent Classification<sup>6</sup> :

C07D 231/12, A61K 31/415

A1

(43) International Publication Date: 8 February 1996 (08.02.96)

(21) International Application Number: PCT/US95/08788

(22) International Filing Date: 20 July 1995 (20.07.95)

(30) Priority Data:  
08/278,297 21 July 1994 (21.07.94) US

(60) Parent Application or Grant

(63) Related by Continuation  
US 08/278,297 (CIP)  
Filed on 21 July 1994 (21.07.94)(71) Applicant (for all designated States except US): G.D. SEARLE  
& CO. [US/US]; Corporate Patent Dept., P.O. Box 5110,  
Chicago, IL 60680-5110 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LEE, Len, F. [US/US];  
2496 Annapolis Way, St. Charles, MO 63033 (US).  
PENNING, Thomas, D. [US/US]; 374 Larch, Elmhurst, IL  
60126 (US). KRAMER, Steven, W. [US/US]; Apartment  
1A, 8832 Kenneth Drive, Des Plaines, IL 60016 (US).  
TALLEY, John, J. [US/US]; 8772 Pine Avenue, Brentwood,  
MO 63144 (US).(74) Agents: BULOCK, Joseph, W. et al.; G.D. Searle & Co.,  
Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-  
5110 (US).(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH,  
CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE,  
KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN,  
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT,  
BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD,  
SZ, UG).


Published

With international search report.

(54) Title: 3,4-SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF INFLAMMATION

(57) Abstract

A class of pyrazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by formula (II), wherein R<sup>1</sup> is selected from alkyl, aralkyl, alkynyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl, arylaminocarbonylalkyl, heterocycli-alkyl, and alkoxycarbonylalkyl; wherein R<sup>3</sup> is aryl optionally substituted at a substitutable position with one or more radicals independently selected from halo, alkylthio, alkylsulfinyl, alkyl, cyano, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, haloalkyl, hydroxyl, alkoxy, hydroxyalkyl, alkoxyalkyl, haloalkoxy, amino, alkylamino, arylamino, heterocyclo and nitro; wherein R<sup>4</sup> is haloalkyl; and wherein R<sup>5</sup> is selected from alkyl and amino; or a pharmaceutically acceptable salt thereof.



(II)

Atty. Docket No. 27880A/USA  
Serial No. 10/803,145  
Karen Seibert  
Reference 92

Best Available Copy

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

### 3,4-SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF INFLAMMATION

#### FIELD OF THE INVENTION

This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating inflammation and inflammation-associated disorders, such as arthritis.

#### BACKGROUND OF THE INVENTION

Prostaglandins play a major role in the inflammation process and the inhibition of prostaglandin production, especially production of PGG<sub>2</sub>, PGH<sub>2</sub> and PGE<sub>2</sub>, has been a common target of antiinflammatory drug discovery. However, common non-steroidal antiinflammatory drugs (NSAIDs) that are active in reducing the prostaglandin-induced pain and swelling associated with the inflammation process are also active in affecting other prostaglandin-regulated processes not associated with the inflammation process. Thus, use of high doses of most common NSAIDs can produce severe side effects, including life threatening ulcers, that limit their therapeutic potential. An alternative to NSAIDs is the use of corticosteroids, which have even more drastic side effects, especially when long term therapy is involved.

Previous NSAIDs have been found to prevent the production of prostaglandins by inhibiting enzymes in the human arachidonic acid/prostaglandin pathway, including the enzyme cyclooxygenase (COX). The recent discovery of an inducible enzyme associated with inflammation (named "cyclooxygenase-2 (COX-2)" or "prostaglandin G/H synthase II") provides a viable target of inhibition which more effectively reduces inflammation and produces fewer and less drastic side effects.

The references below that disclose antiinflammatory activity, show continuing efforts to find a safe and effective antiinflammatory agent. The novel pyrazoles disclosed herein are such safe and also effective antiinflammatory agents furthering such efforts. The invention's compounds are found to show usefulness *in vivo* as antiinflammatory agents with minimal side effects. The substituted pyrazolyl compounds disclosed herein preferably selectively inhibit cyclooxygenase-2 over cyclooxygenase-1.

Pyrazoles have been described for use in the treatment of inflammation. U.S. Patent No. 5,134,142 to Matsuo et al. describes 1,5-diaryl pyrazoles, and specifically, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-trifluoromethyl pyrazole, as having anti-inflammatory activity. Co-pending applications Serial Nos. 8/160,553 and 8/160,594 describe substituted 1,5-substituted pyrazoles for the treatment of inflammation.

U.S. Patent No. 3,254,093, to Huisgen et al, describes a process for preparing pyrazoles. Ethyl [1-benzyl-3-phenyl-pyrazole]carboxylic acid is described.

WO 8300330, published February 3, 1983, describes a process for the preparation of 3,4-diphenyl-5-methyl pyrazolyl derivatives. WO 9219615, published November 12, 1992, describes pyrazolyl compounds having fungicidal properties. U.S. Patent No. 4,968,681, to Hübsch et al., describes (pyrazol-5-yl)hydroxylamines as agents for the treatment of lipoproteinaemia.


U.S. Patent No. 3.984,431, to Guérémy and Renault, describes derivatives of pyrazolyl-5-acetic acid as having antiinflammatory activity. Specifically, [1-isobutyl-3,4-diphenyl-1H-pyrazol-5-yl]acetic acid is described.

The invention's pyrazolyl compounds are found to show usefulness *in vivo* as antiinflammatory agents with minimal side effects.



## DESCRIPTION OF THE INVENTION

A class of substituted pyrazolyl compounds useful in treating inflammation-related disorders is defined by Formula I:



(I)

wherein R<sup>1</sup> is selected from hydrido, alkyl, alkenyl, alkynyl, haloalkyl, aralkyl, heterocycloalkyl, heteroaralkyl, hydroxyalkyl, alkoxyalkyl, cyanoalkyl, aminoalkyl, alkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, alkylaminocarbonylalkyl, N-hydroxyaminocarbonylalkyl, N-hydroxy-N-alkylaminocarbonylalkyl, arylaminocarbonylalkyl and aminocarbonylalkyl;

wherein R<sup>2</sup> and R<sup>3</sup> are independently selected from aryl, cycloalkyl, cycloalkenyl and heterocyclo, wherein R<sup>2</sup> and R<sup>3</sup> are optionally substituted at a substitutable position with one or more radicals independently selected from alkylsulfonyl, aminosulfonyl, haloalkylsulfonyl, halo, alkylthio, alkylsulfinyl, alkyl, cyano, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, haloalkyl, hydroxyl, alkoxy, hydroxyalkyl, alkoxyalkyl, haloalkoxy, amino, alkylamino, arylamino, heterocyclo and nitro; and

wherein R<sup>4</sup> is selected from hydrido, alkyl, haloalkyl, cyano, acyl, alkoxy, carboxyl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aminocarbonyl, heteroaryl, alkylaminocarbonyl, arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, aminocarbonylalkyl, hydroxyalkyl and aralkoxyalkyl;

provided one of  $R^2$  and  $R^3$  are substituted with a radical selected from alkylsulfonyl, aminosulfonyl, and haloalkylsulfonyl;

or a pharmaceutically-acceptable salt thereof.

Compounds of Formula I would be useful for, but not limited to, the treatment of inflammation in a subject, and for treatment of other inflammation-associated disorders, such as, as an analgesic in the treatment of pain and headaches, or as an antipyretic for the treatment of fever. For example, combinations of the invention would be useful to treat arthritis, including but not limited to rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis. Such combinations of the invention would be useful in the treatment of asthma, bronchitis, menstrual cramps, tendinitis, bursitis, and skin related conditions such as psoriasis, eczema, burns and dermatitis. Combinations of the invention also would be useful to treat gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis and for the prevention of colorectal cancer. Combinations of the invention would be useful in treating inflammation in such diseases as vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, scleroderma, rheumatic fever, type I diabetes, myasthenia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, conjunctivitis, swelling occurring after injury, myocardial ischemia, and the like. The combinations would also be useful for the treatment of certain central nervous system disorders such as alzheimer's disease and dementia. The combinations of the invention are useful as anti-inflammatory agents,

such as for the treatment of arthritis, with the additional benefit of having significantly less harmful side effects. These compositions would also be useful in the treatment of allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis and central nervous system damage resulting from stroke, ischemia and trauma.

Besides being useful for human treatment, these compounds are also useful for treatment of mammals, including horses, dogs, cats, rats, mice, sheep, pigs, etc.

The present compounds may also be used in co-therapies, partially or completely, in place of other conventional antiinflammatories, such as together with steroids, NSAIDs, 5-lipoxygenase inhibitors, LTB<sub>4</sub> antagonists and LTA<sub>4</sub> hydrolase inhibitors.

Suitable LTB<sub>4</sub> inhibitors include, among others, ebselen, Bayer Bay-x-1005, Ciba Geigy compound CGS-25019C, Leo Denmark compound ETH-615, Lilly compound LY-293111, Ono compound ONO-4057, Terumo compound TMK-688, Lilly compounds LY-213024, 264086 and 292728, ONO compound ONO-LB457, Searle compound SC-53228, calcitrol, Lilly compounds LY-210073, LY223982, LY233469, and LY255283, ONO compound ONO-LB-448, Searle compounds SC-41930, SC-50605 and SC-51146, and SK&F compound SKF-104493. Preferably, the LTB<sub>4</sub> inhibitors are selected from ebselen, Bayer Bay-x-1005, Ciba Geigy compound CGS-25019C, Leo Denmark compound ETH-615, Lilly compound LY-293111, Ono compound ONO-4057, and Terumo compound TMK-688.

Suitable 5-LO inhibitors include, among others, masoprocol, tenidap, zileuton, pranlukast, tepoxalin, rilopirox, flezelastine hydrochloride, enazadrem phosphate, and bunaprolast.

The present invention preferably includes compounds which selectively inhibit cyclooxygenase-2 over cyclooxygenase-1. Preferably, the compounds have a

cyclooxygenase-2 IC<sub>50</sub> of less than about 0.5  $\mu$ M, and also have a selectivity ratio of cyclooxygenase-2 inhibition over cyclooxygenase-1 inhibition of at least 50, and more preferably of at least 100. Even more preferably, the compounds have a cyclooxygenase-1 IC<sub>50</sub> of greater than about 1  $\mu$ M, and more preferably of greater than 20  $\mu$ M. Such preferred selectivity may indicate an ability to reduce the incidence of common NSAID-induced side effects.

A preferred class of compounds consists of those compounds of Formula I wherein R<sup>1</sup> is selected from hydrido, lower alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, lower aralkyl, lower heterocycloalkyl, lower heteroaralkyl, lower hydroxyalkyl, lower alkoxyalkyl, lower cyanoalkyl, lower aminoalkyl, lower alkylaminoalkyl, lower carboxyalkyl, lower alkoxycarbonylalkyl, lower alkylaminocarbonylalkyl, lower N-hydroxyaminocarbonylalkyl, lower N-hydroxy-N-alkyl-aminocarbonylalkyl, lower arylaminocarbonylalkyl and lower aminocarbonylalkyl; wherein R<sup>2</sup> and R<sup>3</sup> are independently selected from aryl selected from phenyl, naphthyl and biphenyl, lower cycloalkyl, lower cycloalkenyl and heterocyclo, wherein R<sup>2</sup> and R<sup>3</sup> are optionally substituted at a substitutable position with one or more radicals independently selected from lower alkylsulfonyl, aminosulfonyl, halo, lower haloalkylsulfonyl, lower alkylthio, lower alkyl, lower alkylsulfinyl, cyano, carboxyl, lower alkoxycarbonyl, aminocarbonyl, lower alkylaminocarbonyl, phenylaminocarbonyl, lower N-alkyl-N-arylaminocarbonyl, lower haloalkyl, hydroxyl, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, heterocyclo and nitro; and wherein R<sup>4</sup> is selected from hydrido, lower alkyl, lower haloalkyl, cyano, acyl, lower alkoxy, carboxyl, lower carboxyalkyl, lower alkoxycarbonyl, lower alkoxycarbonylalkyl, lower aralkoxycarbonylalkyl,

aminocarbonyl, heteroaryl, lower alkylaminocarbonyl, lower arylaminocarbonyl, lower N-alkyl-N-arylaminocarbonyl, lower aminocarbonylalkyl, lower hydroxyalkyl and lower aralkoxyalkyl.

A class of compounds of particular interest consists of those compounds of Formula I wherein R<sup>1</sup> is selected from methyl, ethyl, isopropyl, tert-butyl, isobutyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethylenyl, propylenyl, butenyl, pentenyl, isopropylenyl, isobutylenyl, propargyl, benzyl, phenylethyl, phenylpropyl, morpholinomethyl, pyrrolidinylmethyl, piperazinylmethyl, piperidinylmethyl, pyridylmethyl, thienylmethyl, hydroxymethyl, hydroxyethyl, methoxymethyl, ethoxymethyl, cyanomethyl, aminomethyl, methylaminomethyl, formyl, acetyl, propanyl, butanyl, methoxycarbonylmethyl, ethoxycarbonylethyl, N-methylaminocarbonylmethyl, N,N-dimethylaminocarbonylmethyl, N-hydroxyaminocarbonylmethyl, N-hydroxy-N-methylaminocarbonylmethyl, N-phenylaminocarbonylmethyl and aminocarbonylmethyl; wherein R<sup>2</sup> and R<sup>3</sup> are independently selected from phenyl, naphthyl, biphenyl, cyclohexyl, cyclopentyl, cycloheptyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 4-cyclohexenyl, 4-methylcyclohex-4-en-1-yl, 1-cyclopentenyl, pyridyl, thienyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isoquinolinyl, imidazolyl, benzimidazolyl, furyl and pyrazinyl, wherein R<sup>2</sup> and R<sup>3</sup> are optionally substituted at a substitutable position with one or more radicals independently selected from methylsulfonyl, aminosulfonyl, fluoro, chloro, bromo, methylthio, methylsulfinyl, cyano, methyl, ethyl, isopropyl, tert-

butyl, isobutyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, propoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, pentoxycarbonyl, aminocarbonyl, N-methylaminocarbonyl, N-ethylaminocarbonyl, N-isopropylaminocarbonyl, N-propylaminocarbonyl, N-butylaminocarbonyl, N-isobutylaminocarbonyl, N-tert-butylaminocarbonyl, N-pentylaminocarbonyl, N,N-dimethylaminocarbonyl, N-methyl-N-ethylaminocarbonyl, N-phenylaminocarbonyl, N-(3-fluorophenyl)aminocarbonyl, N-(4-methylphenyl)aminocarbonyl, N-(3-chlorophenyl)aminocarbonyl, N-(4-methoxyphenyl)aminocarbonyl, N-methyl-N-phenylaminocarbonyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxyl, methoxy, methylenedioxy, ethoxy, propoxy, n-butoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxymethyl, amino, N-methylamino, N,N-dimethylamino, N-methyl-N-phenylamino, N-phenylamino, morpholino, pyrrolidinyl, piperazinyl and piperidinyl and nitro; and wherein R<sup>4</sup> is selected from hydrido, methyl, ethyl, isopropyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, n-butoxy, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyano, formyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, propoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, pentoxycarbonyl, methoxycarbonylalkyl, benzyloxycarbonylmethyl, aminocarbonyl, N-methylaminocarbonyl, N-

ethylaminocarbonyl, N-isopropylaminocarbonyl, N-propylaminocarbonyl, N-butylaminocarbonyl, N-isobutylaminocarbonyl, N-tert-butylaminocarbonyl, N-pentylaminocarbonyl, N,N-dimethylaminocarbonyl, N-methyl-N-ethylaminocarbonyl, N-phenylaminocarbonyl, N-(3-fluorophenyl)aminocarbonyl, N-(4-methylphenyl)aminocarbonyl, N-(3-chlorophenyl)aminocarbonyl, N-(4-methoxyphenyl)aminocarbonyl, N-methyl-N-phenylaminocarbonyl, aminocarbonylmethyl, hydroxypropyl, hydroxymethyl, hydroxyethyl, butanyl, acetyl, propanyl and benzyloxymethyl.

A family of specific compounds of particular interest within Formula I consists of compounds and pharmaceutically-acceptable salts thereof as follows:

4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(2,4-dichlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(3,4-dichlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-bromophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(3-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(2-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-phenyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-(4-trifluoromethoxyphenyl)-5-(trifluoromethyl)-1H-pyrazole;  
4-(2-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;

- 4-(3-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(4-fluoro-2-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(3,5-dimethyl-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(4-methoxy-3-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(4-fluoro-2-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(2,4-dimethylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(3,4-dimethylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(2,5-dichlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(4-n-butoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(2-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(2-pyridyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(3-pyridyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(4-pyridyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(4-aminophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(4-acetamidophenyl)-3-[4-(methylsulfonyl)phenyl]-5-



(trifluoromethyl)-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-(4-trifluoroacetamidophenyl)-5-(trifluoromethyl)-1H-pyrazole;  
4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(3,5-dichloro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(3,5-difluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-(methylthio)phenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(3-chloro-4-(methylthio)phenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-[3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzoic acid;  
methyl 4-[3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzoate;  
4-[3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzamide;  
5-(difluoromethyl)-1-methyl-4-(4-pyridyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1,5-dimethyl-4-(4-pyridyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
5-(hydroxymethyl)-1-methyl-4-(4-pyridyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
methyl [1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
ethyl [1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;

isopropyl [1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
tert-butyl [1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
benzyl [1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
[1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylic acid;  
[1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-phenyl-[1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-methyl-[1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N,N-dimethyl-[1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-methyl-N-phenyl-[1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(2,4-dichlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(3,4-dichlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-bromophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(3-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(2-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-pyrazole;  
4-(4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-(4-

trifluoromethoxyphenyl)-1H-pyrazole;  
4-(2-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(3-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-fluoro-2-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(3,5-dimethyl-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-methoxy-3-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-fluoro-2-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(2,4-dimethylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(3,4-dimethylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(2,5-dichlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-n-butoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(2-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-(2-pyridyl)-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-(3-pyridyl)-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazole;  
4-(4-aminophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-acetamidophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

3-[4-(methylsulfonyl)phenyl]-4-(4-trifluoroacetamidophenyl)-1H-pyrazole;  
4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(3,5-dichloro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(3,5-difluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-(methylthio)phenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(3-chloro-4-(methylthio)phenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-[3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-4-yl]benzoic acid;  
methyl 4-[3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-4-yl]benzoate;  
4-[3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-4-yl]benzamide;  
4-(4-chlorophenyl)-5-(difluoromethyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
5-(chlorodifluoromethyl)-4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1H-pyrazole;  
4-(4-chlorophenyl)-5-cyano-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-chlorophenyl)-5-methyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-chlorophenyl)-5-ethyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(hydroxymethyl)-1H-pyrazole;  
5-(benzyloxymethyl)-4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
[4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-

pyrazol-5-yl]carboxylic acid;  
methyl [4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;  
ethyl [4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;  
t-butyl [4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;  
benzyl [4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;  
isopropyl [4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;  
[4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;  
N-phenyl-[4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;  
N-methyl-N-phenyl-[4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;  
N,N-dimethyl-[4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;  
N-(3-chlorophenyl)-[4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;  
4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(difluoromethyl)-1H-pyrazole;  
4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(chlorodifluoromethyl)-1H-pyrazole;  
4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1H-pyrazole;  
[4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-

pyrazol-5-yl]carboxylic acid;  
methyl [4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;  
[4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;  
N-phenyl-[4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;  
4-(4-fluorophenyl)-1-methyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
1-ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
1-benzyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-cyanomethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-[2-(1H-pyrrolidin-1-yl)ethyl]-5-(trifluoromethyl)-1H-pyrazole;  
ethyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
N-phenyl-[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;  
[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-

(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
4-(4-fluorophenyl)-1-(3-hydroxypropyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-[2-(2-pyridyl)ethyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-5-(trifluoromethyl)-1H-pyrazole;  
N-hydroxy-N-methyl-[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
1-[2-(dimethylamino)ethyl]-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
1-methyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
1-ethyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
1-benzyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-cyanomethyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
ethyl [4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
[4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;  
1-(3-hydroxypropyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-

pyrazole;

1-[2-(dimethylamino)ethyl]-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;

4-(4-chlorophenyl)-1-methyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;

4-(4-chlorophenyl)-1-ethyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;

1-benzyl-4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;

4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazole;

4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazole;

4-(4-chlorophenyl)-1-cyanomethyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;

ethyl [4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;

[4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;

4-(4-chlorophenyl)-1-(3-hydroxypropyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;

4-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;

1-methyl-3-[4-(methylsulfonyl)phenyl]-4-phenyl-5-(trifluoromethyl)-1H-pyrazole;

1-ethyl-3-[4-(methylsulfonyl)phenyl]-4-phenyl-5-(trifluoromethyl)-1H-pyrazole;

1-benzyl-3-[4-(methylsulfonyl)phenyl]-4-phenyl-5-(trifluoromethyl)-1H-pyrazole;



3-[4-(methylsulfonyl)phenyl]-4-phenyl-1-(3-propenyl)-  
5-(trifluoromethyl)-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-phenyl-1-(3-propynyl)-  
5-(trifluoromethyl)-1H-pyrazole;  
1-cyanomethyl-3-[4-(methylsulfonyl)phenyl]-4-phenyl-5-  
(trifluoromethyl)-1H-pyrazole;  
ethyl [3-[4-(methylsulfonyl)phenyl]-4-phenyl-5-  
(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
[3-[4-(methylsulfonyl)phenyl]-4-phenyl-5-  
(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;  
1-(3-hydroxypropyl)-3-[4-(methylsulfonyl)phenyl]-4-  
phenyl-5-(trifluoromethyl)-1H-pyrazole;  
1-[2-(dimethylamino)ethyl]-3-[4-  
(methylsulfonyl)phenyl]-4-phenyl-5-  
(trifluoromethyl)-1H-pyrazole;  
4-(4-methoxyphenyl)-1-methyl-3-[4-  
(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-  
pyrazole;  
1-ethyl-4-(4-methoxyphenyl)-3-[4-  
(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-  
pyrazole;  
1-benzyl-4-(4-methoxyphenyl)-3-[4-  
(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-  
pyrazole;  
4-(4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-  
propenyl)-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-  
propynyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-cyanomethyl-4-(4-methoxyphenyl)-3-[4-  
(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-  
pyrazole;  
ethyl [4-(4-methoxyphenyl)-3-[4-  
(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-  
pyrazol-1-yl]acetate;  
[4-(4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-  
(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;  
1-(3-hydroxypropyl)-4-(4-methoxyphenyl)-3-[4-

- (methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 1-[2-(dimethylamino)ethyl]-4-(4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(2,4-dichlorophenyl)-1-methyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(2,4-dichlorophenyl)-1-ethyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 1-benzyl-4-(2,4-dichlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(2,4-dichlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazole;
- 4-(2,4-dichlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazole;
- 1-cyanomethyl-4-(2,4-dichlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- ethyl [4-(2,4-dichlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;
- [4-(2,4-dichlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;
- 4-(2,4-dichlorophenyl)-1-(3-hydroxypropyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(2,4-dichlorophenyl)-1-[2-(dimethylamino)ethyl]-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 1-methyl-4-(2-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 1-ethyl-4-(2-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-

pyrazole;  
1-benzyl-4-(2-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(2-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazole;  
4-(2-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-cyanomethyl-4-(2-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
ethyl [4-(2-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
[4-(2-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;  
1-(3-hydroxypropyl)-4-(2-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
1-[2-(dimethylamino)ethyl]-4-(2-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-methoxy-3-methylphenyl)-1-methyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
1-ethyl-4-(4-methoxy-3-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
1-benzyl-4-(4-methoxy-3-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-methoxy-3-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-methoxy-3-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazole;

- 1-cyanomethyl-4-(4-methoxy-3-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- ethyl [4-(4-methoxy-3-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;
- [4-(4-methoxy-3-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;
- 1-(3-hydroxypropyl)-4-(4-methoxy-3-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 1-[2-(dimethylamino)ethyl]-4-(4-methoxy-3-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(3-fluoro-4-methoxyphenyl)-1-methyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 1-ethyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 1-benzyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazole;
- 4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazole;
- 1-cyanomethyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- ethyl [4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;
- [4-(3-fluoro-4-methoxyphenyl)-3-[4-

- (methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;
- 4-(3-fluoro-4-methoxyphenyl)-1-(3-hydroxypropyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 1-[2-(dimethylamino)ethyl]-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(3-fluoro-4-methylphenyl)-1-methyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 1-ethyl-4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 1-benzyl-4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazole;
- 4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazole;
- 1-cyanomethyl-4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- ethyl [4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;
- [4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;
- 4-(3-fluoro-4-methylphenyl)-1-(3-hydroxypropyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 1-[2-(dimethylamino)ethyl]-4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-

(trifluoromethyl)-1H-pyrazole;  
1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-ethyl-3-[4-(methylsulfonyl)phenyl]-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-benzyl-3-[4-(methylsulfonyl)phenyl]-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-(4-(methylthio)phenyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-(4-(methylthio)phenyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-cyanomethyl-3-[4-(methylsulfonyl)phenyl]-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazole;  
ethyl [3-[4-(methylsulfonyl)phenyl]-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
[3-[4-(methylsulfonyl)phenyl]-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;  
1-(3-hydroxypropyl)-3-[4-(methylsulfonyl)phenyl]-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-[2-(dimethylamino)ethyl]-3-[4-(methylsulfonyl)phenyl]-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazole;  
4-(1-cyclohexenyl)-1-ethyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-cyanophenyl)-1-ethyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
  
1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-ethyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-benzyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;

3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-cyanomethyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
ethyl [3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
methyl [3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
N-phenyl [3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
[3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;  
[3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
1-(3-hydroxypropyl)-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1-[2-(2-pyridyl)ethyl]-5-(trifluoromethyl)-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-[2-(dimethylamino)ethyl]-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
N-hydroxy-N-methyl-[3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;

1-methyl-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-ethyl-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-benzyl-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazole;

4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-cyanomethyl-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
ethyl [4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
methyl [4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
N-phenyl [4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
[4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;  
[4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
1-(3-hydroxypropyl)-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-1-[2-(2-pyridyl)ethyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-[2-(dimethylamino)ethyl]-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
N-hydroxy-N-methyl-[4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;

1-ethyl-3-[4-(methylsulfonyl)phenyl]-4-(2-pyrazinyl)-5-(trifluoromethyl)-1H-pyrazole;  
4-(5-chloro-2-thienyl)-1-ethyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
1-ethyl-3-[4-(methylsulfonyl)phenyl]-4-(4-(morpholino)phenyl)-5-(trifluoromethyl)-1H-pyrazole;  
4-cyclohexyl-1-ethyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
1-ethyl-3-[4-(methylsulfonyl)phenyl]-4-(2-thienyl)-5-



(trifluoromethyl)-1H-pyrazole;  
4-(4-fluorophenyl)-1-methyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propynyl)-1H-pyrazole;  
1-cyanomethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-[2-(1H-pyrrolidin-1-yl)ethyl]-1H-pyrazole;  
N-phenyl-[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetamide;  
[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetic acid;  
[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetamide;  
4-(4-fluorophenyl)-1-(3-hydroxypropyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-[2-(2-pyridyl)ethyl]-1H-pyrazole;  
4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;  
N-hydroxy-N-methyl-[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetamide;  
1-[2-(dimethylamino)ethyl]-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-methyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-ethyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-benzyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;  
4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propynyl)-1H-pyrazole;

1-cyanomethyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
ethyl [4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetate;  
[4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetic acid;  
1-(3-hydroxypropyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-[2-(dimethylamino)ethyl]-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-chlorophenyl)-1-methyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-chlorophenyl)-1-ethyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-benzyl-4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;  
4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propynyl)-1H-pyrazole;  
4-(4-chlorophenyl)-1-cyanomethyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
ethyl [4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetate;  
[4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetic acid;  
4-(4-chlorophenyl)-1-(3-hydroxypropyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-methyl-3-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-pyrazole;  
1-ethyl-3-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-pyrazole;  
1-benzyl-3-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-phenyl-1-(3-propenyl)-

1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-phenyl-1-(3-propynyl)-  
1H-pyrazole;  
1-cyanomethyl-3-[4-(methylsulfonyl)phenyl]-4-phenyl-  
1H-pyrazole;  
ethyl [3-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-  
pyrazol-1-yl]acetate;  
[3-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-pyrazol-1-  
yl]acetic acid;  
1-(3-hydroxypropyl)-3-[4-(methylsulfonyl)phenyl]-4-  
phenyl-1H-pyrazole;  
1-[2-(dimethylamino)ethyl]-3-[4-  
(methylsulfonyl)phenyl]-4-phenyl-1H-pyrazole;  
4-(4-methoxyphenyl)-1-methyl-3-[4-  
(methylsulfonyl)phenyl]-1H-pyrazole;  
1-ethyl-4-(4-methoxyphenyl)-3-[4-  
(methylsulfonyl)phenyl]-1H-pyrazole;  
1-benzyl-4-(4-methoxyphenyl)-3-[4-  
(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-  
propenyl)-1H-pyrazole;  
4-(4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-  
propynyl)-1H-pyrazole;  
1-cyanomethyl-4-(4-methoxyphenyl)-3-[4-  
(methylsulfonyl)phenyl]-1H-pyrazole;  
ethyl [4-(4-methoxyphenyl)-3-[4-  
(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetate;  
[4-(4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-  
pyrazol-1-yl]acetic acid;  
1-(3-hydroxypropyl)-4-(4-methoxyphenyl)-3-[4-  
(methylsulfonyl)phenyl]-1H-pyrazole;  
1-[2-(dimethylamino)ethyl]-4-(4-methoxyphenyl)-3-[4-  
(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(3-fluoro-4-methoxyphenyl)-1-methyl-3-[4-  
(methylsulfonyl)phenyl]-1H-pyrazole;  
1-ethyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-  
(methylsulfonyl)phenyl]-1H-pyrazole;

1-benzyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;  
4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propynyl)-1H-pyrazole;  
1-cyanomethyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
ethyl [4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetate;  
[4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetic acid;  
4-(3-fluoro-4-methoxyphenyl)-1-(3-hydroxypropyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-[2-(dimethylamino)ethyl]-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(3-fluoro-4-methylphenyl)-1-methyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-ethyl-4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-benzyl-4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;  
4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propynyl)-1H-pyrazole;  
1-cyanomethyl-4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
ethyl [4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetate;  
[4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetic acid;  
4-(3-fluoro-4-methylphenyl)-1-(3-hydroxypropyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-[2-(dimethylamino)ethyl]-4-(3-fluoro-4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-

pyrazole;  
4-(4-chlorophenyl)-5-(difluoromethyl)-1-ethyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-chlorophenyl)-1-ethyl-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1H-pyrazole;  
4-(4-chlorophenyl)-5-cyano-1-ethyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-chlorophenyl)-1-ethyl-5-methyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
4-(4-chlorophenyl)-1-ethyl-5-(hydroxymethyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
5-(benzyloxymethyl)-4-(4-chlorophenyl)-1-ethyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
[4-(4-chlorophenyl)-1-ethyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylic acid;  
methyl [4-(4-chlorophenyl)-1-ethyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;  
N-phenyl-[4-(4-chlorophenyl)-1-ethyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;  
1-benzyl-4-(4-chlorophenyl)-5-(difluoromethyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-benzyl-4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1H-pyrazole;  
1-benzyl-4-(4-chlorophenyl)-5-cyano-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-benzyl-4-(4-chlorophenyl)-5-methyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-benzyl-4-(4-chlorophenyl)-5-(hydroxymethyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-benzyl-5-(benzyloxymethyl)-4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
[1-benzyl-4-(4-chlorophenyl)-3-[4-

(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylic acid;

methyl [1-benzyl-4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;

N-phenyl-[1-benzyl-4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;

4-(4-chlorophenyl)-1-(cyanomethyl)-5-(difluoromethyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

4-(4-chlorophenyl)-1-ethyl-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1H-pyrazole;

4-(4-chlorophenyl)-5-cyano-1-(cyanomethyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

4-(4-chlorophenyl)-1-(cyanomethyl)-5-methyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

4-(4-chlorophenyl)-1-(cyanomethyl)-3-[4-(methylsulfonyl)phenyl]-5-(hydroxymethyl)-1H-pyrazole;

5-(benzyloxymethyl)-4-(4-chlorophenyl)-1-(cyanomethyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

[4-(4-chlorophenyl)-1-(cyanomethyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylic acid;

methyl [4-(4-chlorophenyl)-1-(cyanomethyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;

N-phenyl-[4-(4-chlorophenyl)-1-(cyanomethyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;

4-(4-chlorophenyl)-5-(difluoromethyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;

4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1-(3-propenyl)-1H-pyrazole;

4-(4-chlorophenyl)-5-cyano-3-[4-

(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;  
4-(4-chlorophenyl)-5-methyl-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;  
4-(4-chlorophenyl)-5-(hydroxymethyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;  
5-(benzyloxymethyl)-4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;  
4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazol-5-yl]carboxylate;  
N-phenyl-[4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazol-5-yl]carboxamide;  
4-(4-chlorophenyl)-5-(difluoromethyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;  
4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1-(2-phenylethyl)-1H-pyrazole;  
4-(4-chlorophenyl)-5-cyano-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;  
4-(4-chlorophenyl)-5-methyl-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;  
4-(4-chlorophenyl)-5-(hydroxymethyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;  
5-(benzyloxymethyl)-4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;  
[4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxylate;

N-phenyl-[4-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxamide;

5-(difluoromethyl)-1-ethyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

1-ethyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1H-pyrazole;

5-cyano-1-ethyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

1-ethyl-5-methyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

1-ethyl-5-(hydroxymethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

5-(benzyloxymethyl)-1-ethyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

[1-ethyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylic acid;

methyl [1-ethyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;

N-phenyl-[1-ethyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;

1-benzyl-5-(difluoromethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

1-benzyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1H-pyrazole;

1-benzyl-5-cyano-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

1-benzyl-5-methyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

1-benzyl-5-(hydroxymethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

1-benzyl-5-(benzyloxymethyl)-4-(4-methylphenyl)-3-[4-



(methylsulfonyl)phenyl]-1H-pyrazole;  
[1-benzyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylic acid;  
methyl [1-benzyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;  
N-phenyl-[1-benzyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;  
1-(cyanomethyl)-5-(difluoromethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-ethyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1H-pyrazole;  
5-cyano-1-(cyanomethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-(cyanomethyl)-5-methyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-(cyanomethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(hydroxymethyl)-1H-pyrazole;  
5-(benzyloxymethyl)-1-(cyanomethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
[1-(cyanomethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylic acid;  
methyl [1-(cyanomethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;  
N-phenyl-[1-(cyanomethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;  
5-(difluoromethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;  
4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-

(pentafluoroethyl)-1-(3-propenyl)-1H-pyrazole;  
5-cyano-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;  
5-methyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;  
5-(hydroxymethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;  
5-(benzyloxymethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;  
[4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazol-5-yl]carboxylate;  
N-phenyl-[4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazol-5-yl]carboxamide;  
5-(difluoromethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;  
4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1-(2-phenylethyl)-1H-pyrazole;  
5-cyano-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;  
5-methyl-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;  
5-(hydroxymethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;  
5-(benzyloxymethyl)-4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;  
[4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [4-(4-methylphenyl)-3-[4-

(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxylate;

N-phenyl-[4-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxamide;

5-(difluoromethyl)-1-ethyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

1-ethyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1H-pyrazole;

5-cyano-1-ethyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

1-ethyl-4-(3-fluoro-4-methoxyphenyl)-5-methyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

1-ethyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(hydroxymethyl)-1H-pyrazole;

5-(benzyloxymethyl)-1-ethyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

[1-ethyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylic acid;

methyl [1-ethyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;

N-phenyl-[1-ethyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;

1-benzyl-5-(difluoromethyl)-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;

1-benzyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1H-pyrazole;

1-benzyl-5-cyano-4-(3-fluoro-4-methoxyphenyl)-3-[4-

(methylsulfonyl)phenyl]-1H-pyrazole;  
1-benzyl-4-(3-fluoro-4-methoxyphenyl)-5-methyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-benzyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(hydroxymethyl)-1H-pyrazole;  
1-benzyl-5-(benzyloxymethyl)-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
[1-benzyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylic acid;  
methyl [1-benzyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;  
N-phenyl-[1-benzyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;  
1-(cyanomethyl)-5-(difluoromethyl)-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-ethyl-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1H-pyrazole;  
5-cyano-1-(cyanomethyl)-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-(cyanomethyl)-4-(3-fluoro-4-methoxyphenyl)-5-methyl-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
1-(cyanomethyl)-4-(3-fluoro-4-methoxyphenyl)-5-(hydroxymethyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
5-(benzyloxymethyl)-1-(cyanomethyl)-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
[1-(cyanomethyl)-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylic acid;

methoxyphenyl)-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxylate;

N-phenyl-[1-(cyanomethyl)-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]carboxamide;

5-(difluoromethyl)-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;

4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1-(3-propenyl)-1H-pyrazole;

5-cyano-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;

4-(3-fluoro-4-methoxyphenyl)-5-methyl-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;

4-(3-fluoro-4-methoxyphenyl)-5-(hydroxymethyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;

5-(benzyloxymethyl)-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazole;

[4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazol-5-yl]carboxylic acid;

methoxyphenyl)-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazol-5-yl]carboxylate;

N-phenyl-[4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(3-propenyl)-1H-pyrazol-5-yl]carboxamide;

5-(difluoromethyl)-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;

4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-5-(pentafluoroethyl)-1-(2-phenylethyl)-1H-pyrazole;

5-cyano-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;

- 4-(3-fluoro-4-methoxyphenyl)-5-methyl-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;
- 4-(3-fluoro-4-methoxyphenyl)-5-(hydroxymethyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;
- 5-(benzyloxymethyl)-4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole;
- [4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxylic acid;
- methyl [4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxylate;
- N-phenyl-4-[4-(3-fluoro-4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxamide;
- 4-[4-[4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(2,4-dichlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(3,4-dichlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-bromophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(2-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-phenyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-trifluoromethoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(2-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-fluoro-2-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3,5-dimethyl-4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-methoxy-3-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-fluoro-2-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(2,4-dimethylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3,4-dimethylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(2,5-dichlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-ethoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-n-butoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(2-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(2-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-aminophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-acetamidophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-trifluoroacetamidophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3,5-dichloro-4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3,5-difluoro-4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-chloro-4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[[3-[4-(aminosulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzoic acid;  
methyl 4-[3-[4-(aminosulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzoate;  
4-[[3-[4-(aminosulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzamide;  
4-[5-(difluoromethyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1,5-dimethyl-4-(4-pyridyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-(hydroxymethyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
methyl [3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
ethyl [3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;



isopropyl [3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
tert-butyl [3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
benzyl [3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
[3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-methyl-[3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-phenyl-[3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N,N-dimethyl-[3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-methyl-N-phenyl-[3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
[3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylic acid;  
[3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carbonitrile;  
4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-bromophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-chlorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(2-chlorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[phenyl-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-trifluoromethoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(2-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-fluoro-2-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3,5-dimethyl-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-methoxy-3-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-fluoro-2-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(2,4-dimethylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3,4-dimethylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(2,5-dichlorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-ethoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-n-butoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(2-fluorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(2-pyridyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-pyridyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-pyridyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-aminophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-acetamidophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-trifluoroacetamidophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3,5-dichloro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3,5-difluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-(methylthio)phenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-chloro-4-(methylthio)phenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[3-[4-(aminosulfonyl)phenyl]-1H-pyrazol-4-yl]benzoic acid;  
methyl 4-[3-[4-(aminosulfonyl)phenyl]-1H-pyrazol-4-yl]benzoate;  
4-[[3-[4-(aminosulfonyl)phenyl]-1H-pyrazol-4-yl]benzamide;  
4-[4-(4-chlorophenyl)-5-(difluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-(chlorodifluoromethyl)-4-(4-chlorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-5-(pentafluoroethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-5-cyano-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-5-methyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-5-ethyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-5-(hydroxymethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-(benzyloxymethyl)-4-(4-chlorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-

pyrazol-5-yl]carboxylic acid;  
methyl [3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-5-yl]carboxylate;  
ethyl [3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-5-yl]carboxylate;  
tert-butyl [3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-5-yl]carboxylate;  
benzyl [3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-5-yl]carboxylate;  
isopropyl [3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-5-yl]carboxylate;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-5-yl]carboxamide;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-5-yl]carboxamide;  
N-methyl-N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-5-yl]carboxamide;  
N,N-dimethyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-5-yl]carboxamide;  
N-(3-chlorophenyl)-[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-5-yl]carboxamide;  
4-[4-(4-methylphenyl)-5-(difluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-methylphenyl)-5-(chlorodifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-methylphenyl)-5-(pentafluoroethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[3-[4-(aminosulfonyl)phenyl]-4-(4-methylphenyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [3-[4-(aminosulfonyl)phenyl]-4-(4-methylphenyl)-1H-pyrazol-5-yl]carboxylate;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-methylphenyl)-1H-pyrazol-5-yl]carboxamide;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-methylphenyl)-1H-pyrazol-5-yl]carboxamide;  
4-[4-(4-fluorophenyl)-1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-fluorophenyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-fluorophenyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-cyanomethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-fluorophenyl)-1-[2-(1H-pyrrolidin-1-yl)ethyl]-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
ethyl [3-[4-(aminosulfonyl)phenyl]-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
4-[4-(4-fluorophenyl)-1-(3-hydroxypropyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-fluorophenyl)-1-[2-(2-pyridyl)ethyl]-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-fluorophenyl)-1-(2-phenylethyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
N-hydroxy-N-methyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;

- 4-[1-[2-(dimethylamino)ethyl]-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-methyl-4-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-ethyl-4-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-benzyl-4-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-methylphenyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-methylphenyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-cyanomethyl-4-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- ethyl [3-[4-(aminosulfonyl)phenyl]-4-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;
- [3-[4-(aminosulfonyl)phenyl]-4-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;
- 4-[1-(3-hydroxypropyl)-4-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-[2-(dimethylamino)ethyl]-4-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-chlorophenyl)-1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-chlorophenyl)-1-ethyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-benzyl-4-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-chlorophenyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-chlorophenyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-chlorophenyl)-1-cyanomethyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

ethyl [3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;

[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;

4-[4-(4-chlorophenyl)-1-(3-hydroxypropyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-methyl-4-phenyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-ethyl-4-phenyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-benzyl-4-phenyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[phenyl-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[phenyl-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-cyanomethyl-4-phenyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

ethyl [3-[4-(aminosulfonyl)phenyl]-4-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;

[3-[4-(aminosulfonyl)phenyl]-4-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;

4-[1-(3-hydroxypropyl)-4-phenyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-[2-(dimethylamino)ethyl]-4-phenyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

- 4-[4-(4-methoxyphenyl)-1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-ethyl-4-(4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-benzyl-4-(4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-methoxyphenyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-methoxyphenyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-cyanomethyl-4-(4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- ethyl [3-[4-(aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;
- [3-[4-(aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;
- 4-[1-(3-hydroxypropyl)-4-(4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-[2-(dimethylamino)ethyl]-4-(4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(2,4-dichlorophenyl)-1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(2,4-dichlorophenyl)-1-ethyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-benzyl-4-(2,4-dichlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(2,4-dichlorophenyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;



4-[4-(2,4-dichlorophenyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-cyanomethyl-4-(2,4-dichlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

ethyl [3-[4-(aminosulfonyl)phenyl]-4-(2,4-dichlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;

[3-[4-(aminosulfonyl)phenyl]-4-(2,4-dichlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;

4-[4-(2,4-dichlorophenyl)-1-(3-hydroxypropyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(2,4-dichlorophenyl)-1-[2-(dimethylamino)ethyl]-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-methyl-4-(2-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-ethyl-4-(2-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-benzyl-4-(2-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(2-methylphenyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(2-methylphenyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-cyanomethyl-4-(2-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

ethyl [3-[4-(aminosulfonyl)phenyl]-4-(2-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;

[3-[4-(aminosulfonyl)phenyl]-4-(2-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;

4-[1-(3-hydroxypropyl)-4-(2-methylphenyl)-5-

- (trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-[2-(dimethylamino)ethyl]-4-(2-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-methoxy-3-methylphenyl)-1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-ethyl-4-(4-methoxy-3-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-benzyl-4-(4-methoxy-3-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-methoxy-3-methylphenyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-methoxy-3-methylphenyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-cyanomethyl-4-(4-methoxy-3-methylphenyl)-35-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- ethyl [3-[4-(aminosulfonyl)phenyl]-4-(4-methoxy-3-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;
- [3-[4-(aminosulfonyl)phenyl]-4-(4-methoxy-3-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;
- 4-[1-(3-hydroxypropyl)-4-(4-methoxy-3-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-[2-(dimethylamino)ethyl]-4-(4-methoxy-3-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(3-fluoro-4-methoxyphenyl)-1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-

yl]benzenesulfonamide;  
4-[1-ethyl-4-(3-fluoro-4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(3-fluoro-4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methoxyphenyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methoxyphenyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-cyanomethyl-4-(3-fluoro-4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
ethyl [3-[4-(aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
[3-[4-(aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;  
4-[4-(3-fluoro-4-methoxyphenyl)-1-(3-hydroxypropyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-[2-(dimethylamino)ethyl]-4-(3-fluoro-4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methylphenyl)-1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-ethyl-4-(3-fluoro-4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(3-fluoro-4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

- 4-[4-(3-fluoro-4-methylphenyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(3-fluoro-4-methylphenyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-cyanomethyl-4-(3-fluoro-4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- ethyl [3-[4-(aminosulfonyl)phenyl]-4-(3-fluoro-4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;
- [3-[4-(aminosulfonyl)phenyl]-4-(3-fluoro-4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;
- 4-[4-(3-fluoro-4-methylphenyl)-1-(3-hydroxypropyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-[2-(dimethylamino)ethyl]-4-(3-fluoro-4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-methyl-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-ethyl-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-benzyl-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-(methylthio)phenyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[4-(4-(methylthio)phenyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- 4-[1-cyanomethyl-4-(4-(methylthio)phenyl)-5-

(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

ethyl [3-[4-(aminosulfonyl)phenyl]-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;

[3-[4-(aminosulfonyl)phenyl]-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;

4-[1-(3-hydroxypropyl)-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-[2-(dimethylamino)ethyl]-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(1-cyclohexenyl)-1-ethyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-cyanophenyl)-1-ethyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-ethyl-4-(2-pyrazinyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(5-chloro-2-thienyl)-1-ethyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-ethyl-4-(4-(morpholino)phenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[cyclohexyl-1-ethyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-ethyl-4-(2-thienyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-fluorophenyl)-1-methyl-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-ethyl-4-(4-fluorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-benzyl-4-(4-fluorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-fluorophenyl)-1-(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-fluorophenyl)-1-(3-propynyl)-1H-pyrazol-3-

yl]benzenesulfonamide;  
4-[1-cyanomethyl-4-(4-fluorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-fluorophenyl)-1-[2-(1H-pyrrolidin-1-yl)ethyl]-1H-pyrazol-3-yl]benzenesulfonamide;  
ethyl [3-[4-(aminosulfonyl)phenyl]-4-(4-fluorophenyl)-1H-pyrazol-1-yl]acetate;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-fluorophenyl)-1H-pyrazol-1-yl]acetamide;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-fluorophenyl)-1H-pyrazol-1-yl]acetic acid;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-fluorophenyl)-1H-pyrazol-1-yl]acetamide;  
4-[4-(4-fluorophenyl)-1-(3-hydroxypropyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-fluorophenyl)-1-[2-(2-pyridyl)ethyl]-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-fluorophenyl)-1-(2-phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
N-hydroxy-N-methyl[3-[4-(aminosulfonyl)phenyl]-4-(4-fluorophenyl)-1H-pyrazol-1-yl]acetamide;  
4-[1-[2-(dimethylamino)ethyl]-4-(4-fluorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-methyl-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-ethyl-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-methylphenyl)-1-(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-methylphenyl)-1-(3-propynyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-cyanomethyl-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
ethyl [3-[4-(aminosulfonyl)phenyl]-4-(4-methylphenyl)-1H-pyrazol-1-yl]acetate;

[3-[4-(aminosulfonyl)phenyl]-4-(4-methylphenyl)-1H-pyrazol-1-yl]acetic acid;  
4-[1-(3-hydroxypropyl)-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-[2-(dimethylamino)ethyl]-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-1-methyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-1-ethyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(4-chlorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-1-(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-1-(3-propynyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-1-cyanomethyl-1H-pyrazol-3-yl]benzenesulfonamide;  
ethyl [3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-1-yl]acetate;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1H-pyrazol-1-yl]acetic acid;  
4-[4-(4-chlorophenyl)-1-(3-hydroxypropyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-methyl-4-phenyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-ethyl-4-phenyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-phenyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-phenyl-1-(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-phenyl-1-(3-propynyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-cyanomethyl-4-phenyl-1H-pyrazol-3-

yl]benzenesulfonamide;  
ethyl [3-[4-(aminosulfonyl)phenyl]-4-phenyl-1H-pyrazol-1-yl]acetate;  
[3-[4-(aminosulfonyl)phenyl]-4-phenyl-1H-pyrazol-1-yl]acetic acid;  
4-[1-(3-hydroxypropyl)-4-phenyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-[2-(dimethylamino)ethyl]-4-phenyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-methoxyphenyl)-1-methyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-ethyl-4-(4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-methoxyphenyl)-1-(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-methoxyphenyl)-1-(3-propynyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-cyanomethyl-4-(4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
ethyl [3-[4-(aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-1H-pyrazol-1-yl]acetate;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-methoxyphenyl)-1H-pyrazol-1-yl]acetic acid;  
4-[1-(3-hydroxypropyl)-4-(4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-[2-(dimethylamino)ethyl]-4-(4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methoxyphenyl)-1-methyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-ethyl-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methoxyphenyl)-1-(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;



4-[4-(3-fluoro-4-methoxyphenyl)-1-(3-propynyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-cyanomethyl-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
ethyl [3-[4-(aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]acetate;  
[3-[4-(aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]acetic acid;  
4-[4-(3-fluoro-4-methoxyphenyl)-1-(3-hydroxypropyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-[2-(dimethylamino)ethyl]-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methylphenyl)-1-methyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-ethyl-4-(3-fluoro-4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(3-fluoro-4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methylphenyl)-1-(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methylphenyl)-1-(3-propynyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-cyanomethyl-4-(3-fluoro-4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
ethyl [3-[4-(aminosulfonyl)phenyl]-4-(3-fluoro-4-methylphenyl)-1H-pyrazol-1-yl]acetate;  
[3-[4-(aminosulfonyl)phenyl]-4-(3-fluoro-4-methylphenyl)-1H-pyrazol-1-yl]acetic acid;  
4-[4-(3-fluoro-4-methylphenyl)-1-(3-hydroxypropyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-[2-(dimethylamino)ethyl]-4-(3-fluoro-4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-5-(difluoromethyl)-1-ethyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-1-ethyl-5-(pentafluoroethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-chlorophenyl)-5-cyano-1-ethyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-1-ethyl-5-methyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-1-ethyl-5-(hydroxymethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-(benzyloxymethyl)-4-(4-chlorophenyl)-1-ethyl-1H-pyrazol-3-yl]benzenesulfonamide;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1-ethyl-1H-pyrazol-5-yl]carboxylic acid;  
methyl [3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1-ethyl-1H-pyrazol-5-yl]carboxylate;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1-ethyl-1H-pyrazol-5-yl]carboxamide;  
4-[1-benzyl-4-(4-chlorophenyl)-5-(difluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(4-chlorophenyl)-5-(pentafluoroethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(4-chlorophenyl)-5-cyano-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(4-chlorophenyl)-5-methyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(4-chlorophenyl)-5-(hydroxymethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-5-(benzyloxymethyl)-4-(4-chlorophenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
[3-[4-(aminosulfonyl)phenyl]-1-benzyl-4-(4-chlorophenyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [3-[4-(aminosulfonyl)phenyl]-1-benzyl-4-(4-chlorophenyl)-1H-pyrazol-5-yl]carboxylate;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-1-benzyl-4-(4-chlorophenyl)-1H-pyrazol-5-yl]carboxamide;  
4-[4-(4-chlorophenyl)-1-(cyanomethyl)-5-(difluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-chlorophenyl)-1-ethyl-5-(pentafluoroethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-5-cyano-1-(cyanomethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-1-(cyanomethyl)-5-methyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-1-(cyanomethyl)-5-(hydroxymethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-(benzyloxymethyl)-4-(4-chlorophenyl)-1-(cyanomethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1-(cyanomethyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1-(cyanomethyl)-1H-pyrazol-5-yl]carboxylate;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1-(cyanomethyl)-1H-pyrazol-5-yl]carboxamide;  
4-[4-(4-chlorophenyl)-5-(difluoromethyl)-1-(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-5-(pentafluoroethyl)-1-(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-5-cyano-1-(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-5-methyl-1-(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-chlorophenyl)-5-(hydroxymethyl)-1-(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-(benzyloxymethyl)-4-(4-chlorophenyl)-1-(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1-(3-propenyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1-(3-propenyl)-1H-pyrazol-5-yl]carboxylate;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-

chlorophenyl)-1-(3-propenyl)-1H-pyrazol-5-yl]carboxamide;

4-[4-(4-chlorophenyl)-5-(difluoromethyl)-1-(2-phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-chlorophenyl)-5-(pentafluoroethyl)-1-(2-phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-chlorophenyl)-5-cyano-1-(2-phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-chlorophenyl)-5-methyl-1-(2-phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[4-(4-chlorophenyl)-5-(hydroxymethyl)-1-(2-phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[5-(benzyloxymethyl)-4-(4-chlorophenyl)-1-(2-phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxylic acid;

methyl [3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxylate;

N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-chlorophenyl)-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxamide;

4-[5-(difluoromethyl)-1-ethyl-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-ethyl-4-(4-methylphenyl)-5-(pentafluoroethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[5-cyano-1-ethyl-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-ethyl-5-methyl-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-ethyl-5-(hydroxymethyl)-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[5-(benzyloxymethyl)-1-ethyl-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;

[3-[4-(aminosulfonyl)phenyl]-1-ethyl-4-(4-methylphenyl)-1H-pyrazol-5-yl]carboxylic acid;

methyl [3-[4-(aminosulfonyl)phenyl]-1-ethyl-4-(4-

methylphenyl)-1H-pyrazol-5-yl]carboxylate;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-1-ethyl-4-(4-methylphenyl)-1H-pyrazol-5-yl]carboxamide;  
4-[1-benzyl-5-(difluoromethyl)-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(4-methylphenyl)-5-(pentafluoroethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-5-cyano-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-5-methyl-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-5-(hydroxymethyl)-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-5-(benzyloxymethyl)-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
[3-[4-(aminosulfonyl)phenyl]-1-benzyl-4-(4-methylphenyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [3-[4-(aminosulfonyl)phenyl]-1-benzyl-4-(4-methylphenyl)-1H-pyrazol-5-yl]carboxylate;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-1-benzyl-4-(4-methylphenyl)-1H-pyrazol-5-yl]carboxamide;  
4-[1-(cyanomethyl)-5-(difluoromethyl)-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-ethyl-4-(4-methylphenyl)-(pentafluoroethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-cyano-1-(cyanomethyl)-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-(cyanomethyl)-5-methyl-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-(cyanomethyl)-4-(4-methylphenyl)-(hydroxymethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-(benzyloxymethyl)-1-(cyanomethyl)-4-(4-methylphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
[3-[4-(aminosulfonyl)phenyl]-1-(cyanomethyl)-4-(4-methylphenyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [3-[4-(aminosulfonyl)phenyl]-1-(cyanomethyl)-4-(4-methylphenyl)-1H-pyrazol-5-yl]carboxylate;

N-phenyl-[3-[4-(aminosulfonyl)phenyl]-1-(cyanomethyl)-  
4-(4-methylphenyl)-1H-pyrazol-5-yl]carboxamide;  
4-[5-(difluoromethyl)-4-(4-methylphenyl)-1-(3-  
propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-methylphenyl)-5-(pentafluoroethyl)-1-(3-  
propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-cyano-4-(4-methylphenyl)-1-(3-propenyl)-1H-  
pyrazol-3-yl]benzenesulfonamide;  
4-[5-methyl-4-(4-methylphenyl)-1-(3-propenyl)-1H-  
pyrazol-3-yl]benzenesulfonamide;  
4-[5-(hydroxymethyl)-4-(4-methylphenyl)-1-(3-  
propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-(benzyloxymethyl)-4-(4-methylphenyl)-1-(3-  
propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-methylphenyl)-1-(3-  
propenyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [3-[4-(aminosulfonyl)phenyl]-4-(4-  
methylphenyl)-1-(3-propenyl)-1H-pyrazol-5-  
yl]carboxylate;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-  
methylphenyl)-1-(3-propenyl)-1H-pyrazol-5-  
yl]carboxamide;  
4-[5-(difluoromethyl)-4-(4-methylphenyl)-1-(2-  
phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-methylphenyl)-5-(pentafluoroethyl)-1-(2-  
phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-cyano-4-(4-methylphenyl)-1-(2-phenylethyl)-1H-  
pyrazol-3-yl]benzenesulfonamide;  
4-[5-methyl-4-(4-methylphenyl)-1-(2-phenylethyl)-1H-  
pyrazol-3-yl]benzenesulfonamide;  
4-[5-(hydroxymethyl)-4-(4-methylphenyl)-1-(2-  
phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-(benzyloxymethyl)-4-(4-methylphenyl)-1-(2-  
phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-methylphenyl)-1-(2-  
phenylethyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [3-[4-(aminosulfonyl)phenyl]-4-(4-

methylphenyl)-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxylate;

N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-methylphenyl)-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxamide;

4-[5-(difluoromethyl)-1-ethyl-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-ethyl-4-(3-fluoro-4-methoxyphenyl)-5-(pentafluoroethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[5-cyano-1-ethyl-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-ethyl-4-(3-fluoro-4-methoxyphenyl)-5-methyl-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-ethyl-4-(3-fluoro-4-methoxyphenyl)-5-(hydroxymethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[5-(benzyloxymethyl)-1-ethyl-4-(3-fluoro-4-methoxyphenyl)-1-pyrazol-3-yl]benzenesulfonamide;

[3-[4-(aminosulfonyl)phenyl]-1-ethyl-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-5-yl]carboxylic acid;

methyl [3-[4-(aminosulfonyl)phenyl]-1-ethyl-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-5-yl]carboxylate;

N-phenyl-[3-[4-(aminosulfonyl)phenyl]-1-ethyl-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-5-yl]carboxamide;

4-[1-benzyl-5-(difluoromethyl)-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-benzyl-4-(3-fluoro-4-methoxyphenyl)-5-(pentafluoroethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-benzyl-5-cyano-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-benzyl-4-(3-fluoro-4-methoxyphenyl)-5-methyl-1H-

pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(3-fluoro-4-methoxyphenyl)-5-(hydroxymethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-5-(benzyloxymethyl)-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
[3-[4-(aminosulfonyl)phenyl]-1-benzyl-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [3-[4-(aminosulfonyl)phenyl]-1-benzyl-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-5-yl]carboxylate;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-1-benzyl-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-5-yl]carboxamide;  
4-[1-(cyanomethyl)-5-(difluoromethyl)-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-ethyl-4-(3-fluoro-4-methoxyphenyl)-3,5-(pentafluoroethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-cyano-1-(cyanomethyl)-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-(cyanomethyl)-4-(3-fluoro-4-methoxyphenyl)-5-methyl-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-(cyanomethyl)-4-(3-fluoro-4-methoxyphenyl)-5-(hydroxymethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-(benzyloxymethyl)-1-(cyanomethyl)-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
[3-[4-(aminosulfonyl)phenyl]-1-(cyanomethyl)-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [3-[4-(aminosulfonyl)phenyl]-1-(cyanomethyl)-4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-5-yl]



carboxylate;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-1-(cyanomethyl)-  
4-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-5-yl]  
carboxamide;  
4-[5-(difluoromethyl)-4-(3-fluoro-4-methoxyphenyl)-1-  
(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methoxyphenyl)-5-(pentafluoroethyl)-  
1-(3-propenyl)-1H-pyrazol-3-  
yl]benzenesulfonamide;  
4-[5-cyano-4-(3-fluoro-4-methoxyphenyl)-1-(3-  
propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methoxyphenyl)-5-methyl-1-(3-  
propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methoxyphenyl)-5-(hydroxymethyl)-1-  
(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-(benzyloxymethyl)-4-(3-fluoro-4-methoxyphenyl)-1-  
(3-propenyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
[3-[4-(aminosulfonyl)phenyl]-4-(3-fluoro-4-  
methoxyphenyl)-1-(3-propenyl)-1H-pyrazol-5-  
yl]carboxylic acid;  
methyl [3-[4-(aminosulfonyl)phenyl]-4-(3-fluoro-4-  
methoxyphenyl)-1-(3-propenyl)-1H-pyrazol-5-  
yl]carboxylate;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(3-fluoro-4-  
methoxyphenyl)-1-(3-propenyl)-1H-pyrazol-5-  
yl]carboxamide;  
4-[5-(difluoromethyl)-4-(3-fluoro-4-methoxyphenyl)-1-  
(2-phenylethyl)-1H-pyrazol-3-  
yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methoxyphenyl)-5-(pentafluoroethyl)-  
1-(2-phenylethyl)-1H-pyrazol-3-  
yl]benzenesulfonamide;  
4-[5-cyano-4-(3-fluoro-4-methoxyphenyl)-1-(2-  
phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methoxyphenyl)-5-methyl-1-(2-  
phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(3-fluoro-4-methoxyphenyl)-5-(hydroxymethyl)-1-

(2-phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[5-(benzyloxymethyl)-4-(3-fluoro-4-methoxyphenyl)-1-(2-phenylethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
[3-[4-(aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxylic acid;  
methyl [3-[4-(aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxylate;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(3-fluoro-4-methoxyphenyl)-1-(2-phenylethyl)-1H-pyrazol-5-yl]carboxamide;  
  
4-[1-methyl-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;  
4-[1-methyl-3-(4-pyridyl)-1H-pyrazol-4-yl]benzenesulfonamide;  
4-[5-(difluoromethyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-4-yl]benzenesulfonamide;  
4-[1,5-dimethyl-3-(4-pyridyl)-1H-pyrazol-4-yl]benzenesulfonamide;  
4-[5-(hydroxymethyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-4-yl]benzenesulfonamide;  
methyl [4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
ethyl [4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
isopropyl [4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
tert-butyl [4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
benzyl [4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
[4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;

N-methyl-[4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-phenyl-[4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N,N-dimethyl-[4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-methyl-N-phenyl-[4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
[4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylic acid;  
[4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carbonitrile;

1-methyl-4-(methanesulfonylphenyl)-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-methyl-3-(4-pyridyl)-4-[4-(methanesulfonylphenyl)-1H-pyrazole];  
5-(difluoromethyl)-1-methyl-3-(4-pyridyl)-4-[4-(methanesulfonylphenyl)-1H-pyrazole];  
1,5-dimethyl-3-(4-pyridyl)-4-[4-(methanesulfonylphenyl)-1H-pyrazole];  
5-(hydroxymethyl)-1-methyl-3-(4-pyridyl)-4-[4-(methanesulfonylphenyl)-1H-pyrazole];  
methyl [1-methyl-4-[4-(methanesulfonylphenyl)-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate];  
ethyl [1-methyl-4-[4-(methanesulfonylphenyl)-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate];  
isopropyl [1-methyl-4-[4-(methanesulfonylphenyl)-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate];  
tert-butyl [1-methyl-4-[4-(methanesulfonylphenyl)-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate];  
benzyl [1-methyl-4-[4-(methanesulfonylphenyl)-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate];  
[1-methyl-4-[4-(methanesulfonylphenyl)-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylic acid];  
[4-[1-methyl-4-(methanesulfonylphenyl)-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide];

N-phenyl-[1-methyl-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-methyl-[1-methyl-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N,N-dimethyl-[1-methyl-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-methyl-N-phenyl-[1-methyl-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
4-[1-ethyl-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-pyridyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-pyridyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-cyanomethyl-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
ethyl [3-[4-(aminosulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
methyl [3-[4-(aminosulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
4-[1-[2-(2-pyridyl)ethyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-(2-phenylethyl)-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
N-hydroxy-N-methyl-[3-(4-aminosulfonyl)phenyl]-4-(4-

pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;

4-[1-(3-hydroxypropyl)-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-[2-(dimethylamino)ethyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;

4-[1-ethyl-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;

4-[1-benzyl-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;

4-[3-(4-pyridyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;

4-[3-(4-pyridyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;

4-[1-cyanomethyl-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;

ethyl [4-[4-(aminosulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;

methyl [4-[4-(aminosulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;

N-phenyl-[4-[4-(aminosulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;

[4-[4-(aminosulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;

[4-[4-(aminosulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;

4-[1-[2-(2-pyridyl)ethyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;

4-[1-(2-phenylethyl)-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;

N-hydroxy-N-methyl-[3-(4-aminosulfonyl)phenyl]-4-(4-


- pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;
- 4-[1-(3-hydroxypropyl)-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;
- 4-[1-[2-(dimethylamino)ethyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;
- 3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-5-(trifluoromethyl)-1H-pyrazole;
- 1-cyanomethyl-3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-1-propargyl)-5-(trifluoromethyl)-1H-pyrazole;
- 1-benzyl-3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-5-(trifluoromethyl)-1H-pyrazole;
- 1-ethyl-3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-1-[2-(1H-pyrrolidin-1-yl)ethyl]-5-(trifluoromethyl)-1H-pyrazole;
- ethyl [3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;
- N-phenyl [3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;
- [3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;
- [3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;

3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-1-allyl-5-trifluoromethyl-1H-pyrazole;

3-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetic acid; and

4-[1-ethyl-3-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide.

Within Formula I there is a subclass of compounds of high interest represented by Formula II:



wherein  $R^1$  is selected from alkyl, aralkyl, alkynyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl, arylaminocarbonylalkyl, heterocycloalkyl, and alkoxy carbonylalkyl;

wherein  $R^3$  is aryl optionally substituted at a substitutable position with one or more radicals independently selected from halo, alkylthio, alkylsulfinyl, alkyl, cyano, carboxyl, alkoxy carbonyl, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, haloalkyl, hydroxyl, alkoxy, hydroxyalkyl, alkoxyalkyl, haloalkoxy, amino, alkylamino, arylamino, heterocyclo and nitro;

wherein  $R^4$  is haloalkyl; and

wherein  $R^5$  is selected from alkyl and amino;

or a pharmaceutically-acceptable salt thereof.

A preferred class of compounds consists of those compounds of Formula II wherein  $R^1$  is selected from lower alkyl, lower aralkyl, lower alkynyl, lower cyanoalkyl, lower carboxyalkyl, lower aminocarbonylalkyl, lower arylaminocarbonylalkyl, lower heterocycloalkyl and lower alkoxy carbonylalkyl; wherein  $R^3$  is aryl selected from phenyl, naphthyl and biphenyl,


wherein said aryl radical is optionally substituted at a substitutable position with one or more radicals independently selected from halo, lower alkylthio, lower alkyl, carboxyl, lower haloalkyl, lower alkoxycarbonyl, aminocarbonyl, lower alkoxy, lower alkylaminocarbonyl, hydroxyl, amino, and lower alkylamino; wherein R<sup>4</sup> is lower haloalkyl; and wherein R<sup>5</sup> is selected from lower alkyl and amino.

A class of compounds of particular interest consists of those compounds of Formula II wherein R<sup>1</sup> is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, benzyl, phenylethyl, phenylpropyl, propargyl, cyanomethyl, cyanoethyl, acetyl, propanyl, butanyl, morpholinomethyl, pyrrolidinylmethyl, piperazinylmethyl, piperidinylmethyl, tetrahydrofurylmethyl, acetamidyl, phenylacetamidyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, isopropoxycarbonylmethyl, tert-butoxycarbonylmethyl, propoxycarbonylethyl, butoxycarbonylethyl, isobutoxycarbonylmethyl, and pentoxycarbonylmethyl; wherein R<sup>3</sup> is phenyl optionally substituted at a substitutable position with one or more radicals selected from fluoro, chloro, bromo, methylthio, methyl, carboxyl, trifluoromethyl, ethoxycarbonyl, aminocarbonyl, methoxy, methylaminocarbonyl, hydroxyl, amino, and N,N-dimethylamino; wherein R<sup>4</sup> is selected from fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl; and wherein R<sup>5</sup> is selected from methyl, ethyl, and amino.

Within Formula I there is a second subclass of compounds of high interest represented by Formula III



75



(III)

wherein R<sup>1</sup> is selected from hydrido, alkyl, aralkyl, alkynyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl, arylaminocarbonylalkyl, heterocycloalkyl, and alkoxycarbonylalkyl;

wherein R<sup>4</sup> is selected from alkyl, haloalkyl, cyano, acyl, alkoxy, carboxyl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aminocarbonyl, heteroaryl, alkylaminocarbonyl, arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, aminocarbonylalkyl, hydroxyalkyl and aralkoxyalkyl;

wherein R<sup>5</sup> is selected from alkyl and amino; and

wherein R<sup>6</sup> is nitrogen-containing heteroaryl optionally substituted at a substitutable position with one or more substituents independently selected from halo, alkyl, alkoxy, alkylthio, amino and alkylamino; or a pharmaceutically-acceptable salt thereof.

A preferred class of compounds consists of those compounds of Formula III wherein R<sup>1</sup> is selected from hydrido, lower alkyl, lower aralkyl, lower alkynyl, lower cyanoalkyl, lower carboxyalkyl, lower aminocarbonylalkyl, lower arylaminocarbonylalkyl, lower heterocycloalkyl and lower alkoxycarbonylalkyl; wherein R<sup>4</sup> is selected from hydrido and lower haloalkyl; wherein R<sup>5</sup> is selected from lower alkyl and amino; and wherein R<sup>6</sup> is nitrogen-containing heteroaryl optionally substituted at a substitutable position with one or more substituents independently selected from halo, lower alkyl, lower alkoxy, lower alkylthio, amino and lower alkylamino.

A class of compounds of particular interest consists of those compounds of Formula III wherein R<sup>1</sup> is selected from hydrido, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *tert*-butyl, benzyl, phenylethyl, phenylpropyl, propargyl, cyanomethyl, cyanoethyl, acetyl, propanyl, butanyl, morpholinomethyl, pyrrolidinylmethyl, piperazinylmethyl, piperidinylmethyl, tetrahydrofurylmethyl, acetamidyl, phenylacetamidyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, isopropoxycarbonylmethyl, *tert*-butoxycarbonylmethyl, propoxycarbonylethyl, butoxycarbonylethyl, isobutoxycarbonylmethyl, and pentoxycarbonylmethyl; wherein R<sup>4</sup> is selected from hydrido, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl; wherein R<sup>5</sup> is selected from methyl, ethyl, and amino; and wherein R<sup>6</sup> is selected from pyridyl, thienyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isoquinolinyl, imidazolyl, and benzimidazolyl, wherein R<sup>6</sup> is optionally substituted at a substitutable position with one or more substituents independently selected from fluoro, chloro, bromo, methyl, ethyl, isopropyl, *tert*-butyl, isobutyl, methoxy, ethoxy, isopropoxy, *tert*-butoxy, propoxy, butoxy, isobutoxy, pentoxy, methylthio, amino, N-methylamino and N,N-dimethylamino.

Compounds of Formula III would also be capable of inhibiting cytokines, such as TNF, IL-1, IL-6, and IL-8. As such, the compounds can be used in the manufacture of a medicament or in a method for the treatment for the prophylactic or therapeutic treatment of diseases mediated by cytokines, such as TNF, IL-1, IL-6, and IL-8.

The term "hydrido" denotes a single hydrogen atom (H). The hydrido radical may be attached, for example, to an oxygen atom to form a hydroxyl radical or two hydrido radicals may be attached to a carbon atom to form a methylene ( $-\text{CH}_2-$ ) radical. Where the term "alkyl" is used, either alone or within other terms such as "haloalkyl", "alkylsulfonyl", "alkoxyalkyl" and "hydroxyalkyl", embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl and the like. Where the term "alkenyl" is used, it embraces linear or branched carbon carbon double bond-containing radicals having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkenyl radicals are "lower alkenyl" radicals having two to about six carbon atoms. Suitable "lower alkenyl" may be a straight or branched radicals, such as vinyl, allyl, isopropenyl, propenyl, butenyl, pentenyl or the like, in which preferably one is isopropenyl. Lower alkenyl may be substituted with cyano. Where the term "alkynyl" is used, it embraces linear or branched carbon carbon triple bond-containing radicals having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkynyl radicals are "lower alkynyl" radicals having two to about six carbon atoms. Suitable "lower alkynyl" may be straight or branched, such as ethynyl, propynyl, propargyl or the like, in which preferably one is propargyl. The term "halo" means halogens such as fluorine, chlorine, bromine or iodine. The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl,

dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. "Lower haloalkyl" embraces radicals having 1 to about 6 carbon atoms. Examples of lower haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. The term "hydroxyalkyl" embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl" radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. The term "cyanoalkyl" embraces radicals having a cyano or nitrile (-CN) radical attached to an alkyl radicals as described above. More preferred cyanoalkyl radicals are "lower cyanoalkyl" radicals having one to six carbon atoms. Examples of such lower cyanoalkyl radicals include cyanomethyl, cyanopropyl, cyanoethyl and cyanobutyl. The terms "alkoxy" and "alkoxyalkyl" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to about six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. The term "alkoxyalkyl" also embraces alkyl radicals having two or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. More preferred alkoxyalkyl

radicals are "lower alkoxyalkyl" radicals having one to six carbon atoms and one or two alkoxy radicals. Examples of such radicals include methoxymethyl, methoxyethyl, ethoxyethyl, methoxybutyl and methoxypropyl. The "alkoxy" or "alkoxyalkyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy or haloalkoxyalkyl radicals. More preferred haloalkoxy radicals are "lower haloalkoxy" radicals having one to six carbon atoms and one or more halo radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy. The term "aryl", alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. Aryl moieties may also be substituted at a substitutable position with one or more substituents selected independently from alkyl, alkoxyalkyl, carboxyalkyl, alkoxy, amino, halo, nitro, alkylamino, acyl, cyano, carboxy, aminocarbonyl, and alkoxycarbonyl. The terms "heterocyclic" and "heterocyclic" embraces saturated, partially saturated and unsaturated heteroatom-containing ring-shaped radicals, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of saturated heterocyclic radicals include saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.]; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl, etc.]; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl, etc.]. Examples of partially saturated heterocyclic radicals

include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole. The term "heteroaryl" embraces unsaturated heterocyclic radicals. Examples of unsaturated heterocyclic radicals, also termed "heteroaryl" radicals include unsaturated 3 to 6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl [e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.] tetrazolyl [e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.], etc.; unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g., tetrazolo [1,5-b]pyridazinyl, etc.], etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, 2-furyl, 3-furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group containing a sulfur atom, for example, 2-thienyl, 3-thienyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.] etc.; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. benzoxazolyl, benzoxadiazolyl, etc.]; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e.g., 1,2,4- thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.] etc.; unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., benzothiazolyl, benzothiadiazolyl, etc.] and the like. The term also embraces radicals where heterocyclic radicals are fused

with aryl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like. Said "heterocyclic group" may be substituted at a substitutable position with one or more substituents selected from halo, alkylthio, alkylsulfinyl, alkyl, cyano, haloalkyl, hydroxyl, alkoxy, hydroxyalkyl and haloalkoxy. More preferred heteroaryl radicals include five to six membered heteroaryl radicals. The term "heterocycloalkyl" embraces heterocyclic-substituted alkyl radicals. More preferred heterocycloalkyl radicals are "lower heterocycloalkyl" radicals having one to six carbon atoms and a heterocyclic radical. Examples include such radicals as pyrrolidinylmethyl. The term "heteroaralkyl" embraces heteroaryl-substituted alkyl radicals. More preferred heteroaralkyl radicals are "lower heteroaralkyl" radicals having one to six carbon atoms and a heteroaryl radical. Examples include such heteroaralkyl radicals such as pyridylmethyl and thienylmethyl. The term "alkylthio" embraces radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms attached to a divalent sulfur atom. More preferred alkylthio radicals are "lower alkylthio" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, butylthio and hexylthio. The term "alkylsulfinyl" embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent  $-S(=O)-$  radical. More preferred alkylsulfinyl radicals are "lower alkylsulfinyl" radicals having one to six carbon atoms. Examples of such lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl. The term "sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals  $-SO_2-$ . "Alkylsulfonyl" embraces alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above. More preferred

alkylsulfonyl radicals are "lower alkylsulfonyl" radicals having one to six carbon atoms. Examples of such lower alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl and propylsulfonyl. The "alkylsulfonyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkylsulfonyl" radicals. More preferred haloalkylsulfonyl radicals are "lower haloalkylsulfonyl" radicals having one or more halo atoms attached to lower alkylsulfonyl radicals as described above. Examples of such lower haloalkylsulfonyl radicals include fluoromethylsulfonyl, trifluoromethylsulfonyl and chloromethylsulfonyl. The terms "sulfamyl", "aminosulfonyl" and "sulfonamidyl" denotes  $\text{NH}_2\text{O}_2\text{S}-$ . The term "acyl" denotes a radical provided by the residue after removal of hydroxyl from an organic acid. Examples of such acyl radicals include alkanoyl and aroyl radicals. The terms "carboxy" or "carboxyl", whether used alone or with other terms, such as "carboxyalkyl", denotes  $-\text{CO}_2\text{H}$ . The term "carbonyl", whether used alone or with other terms, such as "alkoxycarbonyl", denotes  $-(\text{C}=\text{O})-$ . The term "alkoxycarbonyl" means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical. Preferably, "lower alkoxycarbonyl" embraces alkoxy radicals having one to six carbon atoms. Examples of such "alkoxycarbonyl" ester radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl. The term "alkoxycarbonylalkyl" embraces radicals having "alkoxycarbonyl", as defined above substituted to an alkyl radical. More preferred alkoxycarbonyl radicals are "lower alkoxycarbonylalkyl" radicals having alkoxycarbonyl radicals as defined above attached to alkyl radicals having one to six carbon atoms. The term "aryloxycarbonyl" embraces aryl radicals attached to a




carbonyl radical. Examples of similar radicals include substituted or unsubstituted "aryloxy carbonyl" [e.g. phenoxy carbonyl, 4-nitrophenoxy carbonyl, 2-naphthoxy carbonyl, etc.], substituted or unsubstituted "aralkoxy carbonyl" [e.g. benzyloxy carbonyl, phenylethoxy carbonyl, benzhydryloxy carbonyl, 4-nitrobenzyloxy carbonyl, etc.] and the like. The term "carboxyalkyl" embraces radicals having a carboxy radical as defined above, attached to an alkyl radical. The carboxyalkyl radicals may be substituted or unsubstituted, such as formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, trifluoroacetyl or the like, in which the preferable one is formyl, acetyl, propionyl or trifluoroacetyl. The term "aralkyl" embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl. The term "lower aralkyl" includes one or more aryl rings attached to alkyl radicals having one to six carbon atoms. The aryl in said aralkyl may be additionally substituted. The terms benzyl and phenylmethyl are interchangeable. The term "cycloalkyl" embraces saturated carbocyclic radicals having three to twelve carbon atoms. More preferred cycloalkyl radicals are "lower cycloalkyl" radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "cycloalkenyl" embraces unsaturated radicals having three to ten carbon atoms, such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and cycloheptenyl. The term "aralkoxy" embrace oxy-containing aralkyl radicals attached through an oxygen atom to other radicals. The term "aralkoxyalkyl" embraces alkyl radicals having one or more aralkoxy radicals attached to the alkyl radical, that is, to form monoaralkyloxyalkyl and diaralkyloxyalkyl radicals. The "aralkoxy" or "aralkoxyalkyl" radicals may be further

substituted on the aryl ring portion of the radical. The term "aralkoxycarbonylalkyl" embraces aralkoxycarbonyl radicals, as defined above, attached to a carbonyl radical. More preferred aralkoxycarbonylalkyl radicals are "lower aralkoxycarbonylalkyl" radicals having aralkoxycarbonyl radicals attached to alkyl radicals having one to six carbon atoms. The term "aminoalkyl" embraces alkyl radicals substituted with amino radicals. The term "alkylaminoalkyl" embraces aminoalkyl radicals having the nitrogen atom substituted with at least one alkyl radical. The term "alkylamino" denotes amino groups which have been substituted with one or two alkyl radicals. Suitable "alkylamino" may be mono or dialkylamino such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino or the like. The term "arylamino" denotes amino groups which have been substituted with one or two aryl radicals, such as N-phenylamino. The "arylamino" radicals may be further substituted on the aryl ring portion of the radical. The term "aminocarbonyl" denotes an amide group of the formula  $-C(=O)NH_2$ . The term "aminocarbonylalkyl" denotes an aminocarbonyl group which is attached to an alkyl radical. More preferred are "lower aminocarbonylalkyl" having aminocarbonyl radicals as described above attached to one to six carbon atoms. The term "alkylaminocarbonyl" denotes an aminocarbonyl group which has been substituted with one or two alkyl radicals. The term "alkylaminocarbonylalkyl" denotes an alkylaminocarbonyl group which has been attached to an alkyl radical. More preferred are "lower alkylaminocarbonylalkyl" having lower alkylaminocarbonyl radicals as described above attached to one to six carbon atoms. The term "arylamino" denotes an aminocarbonyl group which has been substituted with one or two aryl radicals. The arylaminocarbonyl may be optionally substituted at a substituted position on the

aryl radical with halo, lower alkyl and lower alkoxy radicals. Examples include phenylaminocarbonyl, naphthylamideaminocarbonyl, tolylaminocarbonyl, xylylaminocarbonyl, mesitylaminocarbonyl, cumenylaminocarbonyl, fluorophenylcarbonyl, methylphenylcarbonyl and methoxyphenylcarbonyl. The term "alkyl-aryl-aminocarbonyl" denotes an aminocarbonyl group which has been substituted with one aryl radical and one alkyl radical. The term "hydroxyaminocarbonyl" denotes an aminocarbonyl group which has been substituted with a hydroxy radical. The term "hydroxy-alkyl-aminocarbonyl" denotes an hydroxyaminocarbonyl group which has been substituted with an alkyl radical.

The present invention comprises the tautomeric forms of compounds of Formula I-III. As, illustrated below, the pyrazoles of Formula I and I' are magnetically and structurally equivalent because of the prototropic tautomeric nature of the hydrogen:




The present invention comprises a pharmaceutical composition comprising a therapeutically-effective amount of a compound of Formula I in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.

The present invention also comprises a method of treating inflammation or inflammation-associated disorders in a subject, the method comprising administering to the subject having such inflammation or disorder a therapeutically-effective amount of a compound of Formula I.

Also included in the family of compounds of Formula I are the pharmaceutically-acceptable salts thereof. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of Formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethylsulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, stearic, cyclohexylaminosulfonic, algenic,  $\beta$ -hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, choline, chloroprocaine, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of Formula I by reacting, for example, the appropriate acid or base with the compound of Formula I.


**GENERAL SYNTHETIC PROCEDURES**

The compounds of the invention can be synthesized according to the following procedures of Schemes I-VII, wherein the  $R^1$ - $R^6$  substituents are as defined for Formulas I-III, above, except where further noted.

**Scheme I**

Scheme I shows the procedure for forming substituted aryl ketones 2, where  $R^2$  is phenyl substituted with  $R^5-S$ - where  $R^5$  is alkyl, from the corresponding aryl sulfides 1. Sulfides 1, such as thioanisole, are reacted with a substituted acetic acid, such as a phenyl or cycloalkylacetic acid, under Lewis acid catalyzed conditions, preferably using polyphosphoric acid (PPA) as the Lewis acid, to provide phenyl ketone 2.

## Scheme II




- 5        Scheme II shows the four step procedure for  
 forming pyrazoles 5 of the present invention (where R<sup>5</sup>  
 is alkyl) from ketones 2. In step 1, ketone 2 is  
 reacted with a base, such as lithium  
 bis(trimethylsilyl)amide or lithium diisopropylamide  
 10    (LDA) to form the anion. In step 2, the anion is  
 reacted with an acetylating reagent, preferably 1-  
 trifluoroacetylimidazole or 1-difluoroacetylimidazole,  
 provides diketone 3. In step 3, the reaction of  
 diketone 3 with hydrazine or a substituted hydrazine,  
 15    gives pyrazole 4. In step 4, the pyrazole 4 is  
 oxidized with an oxidizing reagent, such as Oxone<sup>®</sup>  
 (potassium peroxymonosulfate), 3-chloroperbenzoic acid  
 (MCPBA) or hydrogen peroxide, to give a mixture of the  
 desired 3-(alkylsulfonyl)phenyl-pyrazole 5 and the 5-  
 20    (alkylsulfonyl)phenyl-pyrazole isomer. The desired  
 pyrazole 5, usually a white or pale yellow solid, is

obtained in pure form either by chromatography or recrystallization.

Alternatively, diketone 3 can be formed from ketone 2 by treatment with a base, such as sodium hydride, in a solvent, such as dimethylformamide, and further reacting with a nitrile to form an aminoketone. Treatment of the aminoketone with acid forms the diketone 3.


### Scheme III



Scheme III shows an alternative two step synthesis of pyrazole analogs 7 where R<sup>1</sup> is hydrogen.

In Step 1, ketone 2, prepared as described in Scheme I, is heated (100-120°C) with a formamide equivalent, such as DMF-dimethyl acetal, either neat or in DMF to provide enamino-ketone 6. In Step 2, the reaction of enamino-ketone 6 with hydrazine gives the desired pyrazole 7.

## Scheme IV




- 5        Scheme IV shows a procedure for forming the 3-(alkylsulfonyl)phenyl-pyrazoles 8 of the present invention as well as an alternate synthesis of the desired 3-(alkylsulfonyl)phenyl-1-substituted pyrazoles 5 from pyrazoles 7 (where R<sup>1</sup> is hydrogen).
- 10    In step 1, the pyrazole 7 is oxidized with an oxidizing reagent, such as Oxone® (potassium peroxymonosulfate), 3-chloroperbenzoic acid (MCPBA) or hydrogen peroxide to form the desired 3-(alkylsulfonyl)phenyl-pyrazoles 8. In step 2, the
- 15    reaction of 3-(alkylsulfonyl)phenyl-pyrazoles 8 with a variety of alkylating reagents, such as an alkyl halide, in the presence of a base, such as K<sub>2</sub>CO<sub>3</sub>, in a polar aprotic solvent such as DMF, gives a mixture of



the desired 3-(alkylsulfonyl)phenyl-1-substituted pyrazole 5 and the 5-(alkylsulfonyl)phenyl-pyrazole isomer. The desired pyrazole 5 is purified, such as by chromatography or recrystallization.

5        Pyrazoles of the invention also can be prepared by the method of Merkle et al. (WO 95/06036).

### Scheme V



10

12

11

Scheme V shows an alternate method for preparing antiinflammatory pyrazoles with various  $\text{R}^4$  substituents. In Step 1, pyrazoles 9, where  $\text{R}^4$  is an ester, (where R is alkyl and n is 0 to 6) are converted to the corresponding acids 10 by saponification, preferably with sodium hydroxide or lithium hydroxide. In Step 2, the acids 10 can be converted into the amides 11 (where  $\text{R}'$  and  $\text{R}''$  are hydrogen or alkyl) by standard peptide amino acid coupling conditions (M. Bodanszky and A. Bodanszky,


15

20

Practice of Peptide Synthesis (1984)) involving conversion of the acid **10** into an activated ester or amide (i.e with carbonyl diimidazole), followed by coupling with an amine. Amides **11** can additionally be prepared using Weinreb trimethyl aluminum conditions (Tetrahedron Lett., **18**, 4171 (1977)) on ester **9**. When the amide **11** is unsubstituted (when R' and R" are hydrogen), the nitrile **12** can be obtained by dehydration.


10

### Scheme VI



15 Pyrazoles of the invention also can be prepared by the method of Merkle et al. (WO 95/06036) as shown in Scheme VI.

## Scheme VII




- 5 Synthetic Scheme VII shows the three step procedure used to prepare sulfonamide antiinflammatory agents 14 and the two step procedure used to prepare fluoromethyl sulfone antiinflammatory agents 15 from their corresponding methyl sulfones 13. In step one, THF solutions of the methyl sulfones 13 at  $-78^\circ\text{C}$  are treated with an alkylolithium reagent, e.g., methylolithium, n-butyllithium, lithium diisopropylamide (LDA), etc. In step two, the anions generated in step one are treated with an organoborane, e.g., triethylborane, tributylborane, etc., at  $-78^\circ\text{C}$  then warmed to ambient temperature prior to stirring at reflux. An alternative to the boron chemistry involves room temperature alkylation, such as with trimethylsilylmethylhalides, followed by treatment with tetrabutylammonium fluoride (1M in THF). In step three, an aqueous solution of sodium acetate and hydroxylamine-O-sulfonic acid is added to provide the corresponding sulfonamide antiinflammatory

agents 14 of this invention. Alternatively, the anion solutions generated in step one may be warmed to 0°C and treated with N-fluorodibenzenesulfonamide to provide the corresponding fluoromethyl sulfone antiinflammatory agents 15 of this invention.

The following examples contain detailed descriptions of the methods of preparation of compounds of Formula I-III. These detailed descriptions fall within the scope, and serve to exemplify, the above described General Synthetic Procedures which form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All parts are by weight and temperatures are in Degrees centigrade unless otherwise indicated.

## Example 1



5            **1-Ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole**

10        Step 1: Preparation of 2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]ethanone

Polyphosphoric acid (PPA) (160 g), warmed to 60 °C, was added to thioanisole (10.1 g, 81.5 mmol) and 4-fluorophenylacetic acid (10.0 g, 65 mmol), and the mixture was heated to 120-125°C under nitrogen with  
15 vigorous stirring for 20 minutes. Upon cooling to 40 °C, ice water and ice were added with vigorous stirring. The temperature was kept below 85 °C during the quench and dissolution of PPA. After cooling to 25 °C, the white solids were filtered off, washed with two portions  
20 of water and dried. Recrystallization from ethyl acetate-hexane afforded the ketone (10.7 g, 63%): mp 139-140 °C. Anal. Calc'd. for C<sub>15</sub>H<sub>13</sub>FOS: C, 69.21, H, 5.03, S, 12.32. Found: C, 68.74, H, 5.09, S, 12.15.

25        Step 2: Preparation of 4-(4-fluorophenyl)-3-[4-(methylthio)phenyl]-5-(trifluoromethyl)-1H-pyrazole

A suspension of 2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]ethanone from Step 1 (11.53 g, 44  
30 mmol) in 225 mL dry tetrahydrofuran (THF) was treated with 52.8 mL lithium bis(trimethylsilyl) amide (1.0 M in THF) at -70 °C under nitrogen for 30 minutes and warmed to 0 °C for 30 minutes. Upon cooling to -70°C, a

solution of 10.0 g (61 mmol) 1-trifluoroacetylimidazole in 25 mL THF was added and the mixture warmed to 0 °C, during which time the solids dissolved. After 45 minutes, the reaction was quenched with saturated aqueous NH<sub>4</sub>Cl. The organic layer was diluted with ethyl acetate, washed sequentially with dilute HCl and brine, dried over MgSO<sub>4</sub> and concentrated in vacuo. The crude mixture was washed with ether to remove unreacted starting ketone and the yellow solid (11.3 g) was used without further purification. The crude mixture (11.3 g) was stirred with 60 mL glacial acetic acid and 4.5 mL hydrazine hydrate at reflux under nitrogen for 18 hours. The acetic acid was removed in vacuo, and the residue dissolved in ethyl acetate, washed sequentially with dilute HCl and brine, dried over MgSO<sub>4</sub> and reconcentrated in vacuo. Recrystallization from chloroform-hexane gave 8.24 g of the pyrazole as a pale yellow solid. Anal. for C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>F<sub>4</sub>S Calc'd.: C, 57.95, H, 3.43, N, 7.95, S, 9.10. Found: C, 57.58, H, 3.50, N, 7.88, S, 8.97.

Step 3: Preparation of 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole


To a solution of the pyrazole from Step 2 (4.0 g, 11.4 mmol) in 150 mL methanol was added a solution of Oxone® (14.0 g, 22.7 mmol) in 50 mL water. After 1 hour the solids were filtered off, washed with ethyl acetate and the filtrate concentrated in vacuo. This mixture was partitioned between ethyl acetate and water, and the organic layer washed with brine, dried over MgSO<sub>4</sub> and reconcentrated in vacuo. Recrystallization from chloroform gave 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (3.98 g, 91%) as a pale yellow solid: mp 219-220 °C. Elemental anal. for C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>F<sub>4</sub>SO<sub>2</sub> Calc'd.: C, 53.12, H,

3.15, N, 7.29, S, 8.34. Found: C, 52.85, H, 3.12, N, 7.21, S, 8.61

Step 4: Preparation of 1-ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole

4-(4-Fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole from step 3 (1.81 g, 4.3 mmol) and ethyl iodide (0.86 g, 5.5 mmol) were stirred vigorously in 20 mL dry dimethylformamide (DMF) with finely powdered potassium carbonate (0.58 g, 4.2 mmol) under nitrogen at 25°C for 18 hours. The mixture was diluted with ethyl acetate and filtered to remove solids. The organic filtrate was washed with two portions of water followed by brine, dried over MgSO<sub>4</sub> and concentrated in vacuo. The desired 1-ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole was isolated by chromatography on silica gel using ethyl acetate/toluene (10/90) as the eluant, giving 0.65 g (69%) of a white solid: mp 133-135.5 °C.


## Example 2



4-(4-Fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-5-(trifluoromethyl)pyrazole

4-(4-Fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (Example 1, Step 3) (0.10 g) was reacted with potassium carbonate (0.065 g) and 2-bromoethylbenzene (0.67 g) in 5 mL of DMF to give a crude mixture of 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-5-(trifluoromethyl)pyrazole and 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-3-(trifluoromethyl)pyrazole. High pressure liquid chromatography (HPLC) purification gave 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-5-(trifluoromethyl)pyrazole (57 mg, 45%), in the first fraction and 32 mg (25%) of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-3-(trifluoromethyl)pyrazole, in the second fraction. 4-(4-Fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-5-(trifluoromethyl)pyrazole was crystallized from ether-hexane: mp 131.5-135°C. 4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-3-(trifluoromethyl)pyrazole was crystallized from ether-hexane: mp 148.5-149.5°C.

### Example 3



25

4-(4-Fluorophenyl)-1-methyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)pyrazole

30

Step 1: Preparation of 3-amino-4,4,4-trifluoro-2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]-2-buten-1-one



A solution of 2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]ethanone (Example 1, Step 1) (21.4 g, 0.082 mol) in 150 ml of DMF was added under nitrogen to a mixture of 80% sodium hydride oil dispersion (2.6 g, 0.087 mol) and 10 mL of DMF in 30 minutes. The resulting mixture was stirred at room temperature for 1 hour. To the above mixture was passed 10 g (0.11 mol) of gaseous trifluoroacetonitrile in 40 minutes while the reaction mixture was analyzed by thin layer chromatography (TLC). The reaction mixture was poured into 400 mL of water and the solid precipitate was filtered and air dried. The solid precipitate was stirred with 300 mL of ether and filtered. The ether filtrate was dried over MgSO<sub>4</sub> and concentrated in vacuo. The residue was recrystallized from 5% ethyl acetate-hexane to give 12.3 g of a 6:1 mixture of 3-amino-4,4,4-trifluoro-2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]-2-buten-1-one and 5-(4-fluorophenyl)-4-[4-(methylthio)-phenyl]-2,6-bis(trifluoromethyl)pyrimidine. This mixture was heated with 100 mL of ether, cooled and filtered. The ether filtrate was concentrated and the residue was recrystallized from 10% ethyl acetate-hexane to give 3-amino-4,4,4-trifluoro-2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]-2-buten-1-one (10.5 g, 36%): mp 122.5-124.5 °C. The combined ethyl acetate-hexane mother liquor was concentrated in vacuo and the residue was purified by HPLC (10% ethyl acetate-hexane). The first fraction gave 5.8 g (16%) of 5-(4-fluorophenyl)-4-[4-(methylthio)-phenyl]-2,6-bis(trifluoromethyl)pyrimidine after recrystallization from 5% ethyl acetate-hexane. The second fraction gave an additional 2.6 g (9%) of 3-amino-4,4,4-trifluoro-2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]-2-buten-1-one after recrystallization from 5% ethyl acetate-hexane.

Step 2: Preparation of 4-(4-fluorophenyl)-1-methyl-3-[4-(methylthio)phenyl]-5-(trifluoromethyl)pyrazole


The ketone from Step 1 (0.35 g) was reacted with 8 mL of 6N HCl and 30 mL of ether for 24 hours. The ether layer was separated, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue (mainly 2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]-4,4,4-trifluoro-1,3-butanedione) was dissolved in 5-10 mL of glacial acetic acid, treated with methylhydrazine (0.4 g) and heated to 110°C for 18 hours and poured into water. The resulting oil (0.36 g) was extracted into methylene chloride, dried over MgSO<sub>4</sub> and concentrated in vacuo to give a mixture of 4-(4-fluorophenyl)-1-methyl-3-[4-(methylthio)phenyl]-5-(trifluoromethyl)pyrazole and 4-(4-fluorophenyl)-1-methyl-5-[4-(methylthio)phenyl]-3-(trifluoromethyl)pyrazole. Purification by HPLC (20% ethyl acetate-hexane) gave 4-(4-fluorophenyl)-1-methyl-3-[4-(methylthio)phenyl]-5-(trifluoromethyl)pyrazole in the first fraction (25 mg, 7%, mp 100-104°C) and 4-(4-fluorophenyl)-1-methyl-5-[4-(methylthio)phenyl]-3-(trifluoromethyl)pyrazole (0.2 g, 54%) in the second fraction.

Step 3: Preparation of 4-(4-fluorophenyl)-1-methyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)pyrazole

To a solution of pyrazole from Step 2 (0.55 mmoles) in glacial acetic acid (5 mL) was added 4 mmoles of 30% hydrogen peroxide. The reaction mixture was stirred at room temperature for 18 hours and poured into water. The insoluble precipitate was filtered, air dried and recrystallized from an appropriate solvent or further purified by HPLC followed by recrystallization from an appropriate solvent. The crude product was purified by chromatotron (40% ethyl acetate-hexane) followed by

recrystallization from ether-hexane to give white prisms (44%): mp 165.5-169°C.


## Example 4



**1-Benzyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)pyrazole**

A mixture of 0.10 g of 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (Example 1, Step 3) and 3.0 g of benzyl bromide was heated at 140°C for 4 days then at 210°C for 1 hour. The reaction mixture was dissolved in 10% ethyl acetate-hexane and filtered. The filtrate was concentrated in vacuo and the residue was purified by HPLC (10% ethyl acetate-hexane). The first fraction was benzyl bromide. The second fraction eluted with 30% ethyl acetate-hexane yielded 1-benzyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)pyrazole (60 mg, 49%): mp 125.5-126.5°C.

## Example 5



5                   4-(4-Fluorophenyl)-3-[4-  
                  (methylsulfonyl)phenyl]-1-propargyl-5-  
                  (trifluoromethyl)-1H-pyrazole

Step 1:   Preparation of 4-(4-fluorophenyl)-3-[4-  
 10           (methylthio)phenyl]-5-(trifluoromethyl)-1H-  
           pyrazole

Crude 2-(4-fluorophenyl)-1-[4-  
 (methylthio)phenyl]-4,4,4-trifluoro-1,3-butanedione  
 (Example 3, Step 2) (1.0 g) was reacted with anhydrous  
 15 hydrazine (0.13 g) in glacial acetic acid. The mixture  
 was held at 80-110°C for 18 hours and poured into  
 water. The resulting solid precipitate was filtered,  
 purified by HPLC and recrystallized from methylene  
 chloride-hexane to give 4-(4-fluorophenyl)-3-[4-  
 20 (methylthio)phenyl]-5-(trifluoromethyl)-1H-pyrazole as  
 a solid (0.88 g, 89%): mp 189-190°C.

Step 2:   Preparation of 4-(4-fluorophenyl)-3-[4-  
           (methylthio)phenyl]-1-propargyl-5-  
 25           (trifluoromethyl)pyrazole


4-(4-Fluorophenyl)-3-[4-(methylthio)phenyl]-5-  
 (trifluoromethyl)-1H-pyrazole (0.15 g) from step 1 was  
 added to potassium carbonate (0.14 g) and propargyl  
 bromide (0.45 g) in 5 mL of DMF. HPLC purification  
 30 gave 4-(4-fluorophenyl)-3-[4-(methylthio)phenyl]-1-

propargyl-5-(trifluoromethyl)pyrazole (35 mg, 22%) in  
the first fraction (mp 144.5-146°C) and 4-(4-  
fluorophenyl)-5-[4-(methylthio)phenyl]-1-propargyl-3-  
(trifluoromethyl)-1H-pyrazole in the second fraction  
5 (87 mg, 56%, mp 135.5-138.5°C).

Step 3: Preparation of 4-(4-fluorophenyl)-3-[4-  
(methylsulfonyl)phenyl]-1-propargyl-5-  
(trifluoromethyl)-1H-pyrazole

10 To a solution of 0.066 mmol of 4-(4-fluorophenyl)-  
3-[4-(methylthio)phenyl]-1-propargyl-5-  
(trifluoromethyl)pyrazole from step 2 in 5 mL of glacial  
acetic acid was added 13 mmol of 30% hydrogen peroxide.  
The reaction mixture was stirred at room temperature for  
15 72 hours and poured into water. The crude product was  
purified by HPLC (40% ethyl acetate-hexane) followed by  
recrystallization from methylene chloride-hexane to give  
4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-  
propargyl-5-(trifluoromethyl)-1H-pyrazole as white  
20 needles (21%): mp 158-159.5°C.

## Example 6



25 **1-Cyanomethyl-4-(4-fluorophenyl)-3-[4-**  
**(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-**  
**pyrazole**

30 A mixture of 4-(4-fluorophenyl)-3-[4-  
(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole

(Example 1, step 3) (0.10 g), 4.2 g of bromoacetonitrile and 3 mL of toluene was heated at reflux for 2 hours. Toluene was distilled off and the mixture was heated at 190 °C for 24 hours. The reaction mixture was diluted  
5 with methylene chloride and filtered through silica gel. The filtrate was concentrated in vacuo and the residue was purified by HPLC (30% ethyl acetate-hexane). The second fraction eluted with 40% ethyl acetate-hexane yielding 1-cyanomethyl-4-(4-fluorophenyl)-3-[4-  
10 (methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (1.2 mg, 11%): mp 192-194°C.

## Example 7



15  
4-(4-Fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole

20 Step 1: Preparation of 3-(dimethylamino)-2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]prop-2-en-1-one

2- (4-Fluorophenyl)-1-[4-(methylthio)phenyl]ethanone from Example 1, Step 1 (17.2 g, 66 mmol) was stirred  
25 with 15 mL dimethylformamide dimethylacetal in 80 mL dry DMF at 120°C for 24 hours under nitrogen. The reaction mixture was cooled, diluted with two volumes of ethyl acetate, and the solution washed successively with water and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was  
30 removed under high vacuum and the resulting brown oil

(23.9 g) was used in the next step without further purification.

Step 2: Preparation of 4-(4-fluorophenyl)-3-[4-(methylthio)phenyl]-1H-pyrazole

5 The crude ketone from step 1 (23.9 g) was stirred in 500 mL methanol and 100 mL water with 8 mL hydrazine hydrate at reflux under nitrogen for 24 hour. The mixture was cooled, concentrated, diluted with ethyl acetate, washed successively with 1N HCl and brine, dried over MgSO<sub>4</sub> and concentrated in vacuo. Recrystallization from ethyl acetate-hexane gave 4-(4-fluorophenyl)-3-[4-(methylthio)phenyl]-1H-pyrazole as a pale yellow solid (16.9 g, 90.1%). Elemental analysis Calc'd for 15 C<sub>16</sub>H<sub>13</sub>N<sub>2</sub>FS: C, 67.58, H, 4.61, N, 9.85, S, 11.28. Found: C, 67.44, H, 4.76, N, 9.69, S, 11.27.

Step 3: Preparation of 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole


20 The sulfide from the previous step (0.57 g, 2 mmol) was stirred in 20 mL methanol and a solution of Oxone® (2.46 g, 4 mmol) in 8 mL water was added. After 1 hour, the solids were filtered off and washed with ethyl acetate and the filtrate concentrated in vacuo. The residue was partitioned between ethyl acetate and water and the organic layer was washed with brine, dried over MgSO<sub>4</sub> and concentrated in vacuo to give 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole as a pale yellow solid (0.61 g, 97%). Elemental 25 analysis for C<sub>16</sub>H<sub>13</sub>N<sub>2</sub>FSO<sub>2</sub> Calc'd: C, 60.75, H, 4.14, N, 8.86, S, 10.14. Found: C, 59.91, H, 4.29, N, 8.50, S, 10.13.

Step 4: Preparation of 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole

35 4-(4-Fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole (0.47 g, 1.5 mmol) from step 3, 2-

bromoethylbenzene (0.42 g, 2.3 mmol) and sodium iodide (0.04 g) were stirred vigorously in 5 mL dry DMF with finely powdered potassium carbonate (0.41 g, 3 mmol) at 50°C under nitrogen for 18 hours. The mixture was cooled, diluted with ethyl acetate and filtered to remove solids. The organic filtrate was washed with two portions of water followed by brine, dried over MgSO<sub>4</sub> and concentrated. The desired 1-phenylethyl isomer was isolated by recrystallization from ethyl acetate-hexane to give 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-1H-pyrazole as white crystals (0.30 g, 71%): mp 170-171°C. Elemental analysis for C<sub>24</sub>H<sub>21</sub>N<sub>2</sub>FSO<sub>2</sub> Calc'd: C, 68.55, H, 5.03, N, 6.66. Found: C, 68.49, H, 5.36, N, 6.58.

## Example 8




**Ethyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate**

4-(4-Fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (Example 1, Step 3) (2.11 g, 5.5 mmol) and ethyl bromoacetate (1.09 g, 6.5 mmol) were stirred vigorously in 15 mL dry DMF with finely powdered potassium carbonate (1.38 g, 10 mmol) under nitrogen at 25°C for 3 hours. The mixture was diluted with ethyl acetate and filtered to remove solids. The organic filtrate was washed with two portions of water followed by brine, dried over MgSO<sub>4</sub> and concentrated in



vacuo. The desired isomer was isolated by chromatography on silica gel, using 10% ethyl acetate/90% heptane as the eluant, to give ethyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate as a white solid (0.87 g, 34%). Elemental analysis for C<sub>21</sub>H<sub>18</sub>N<sub>2</sub>F<sub>4</sub>SO<sub>4</sub> Calc'd: C, 53.62, H, 3.86, N, 5.96, S, 6.82. Found: C, 53.69, H, 3.97, N, 5.87, S, 7.05.

### Example 9




**N-Phenyl-[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide**

Aniline (0.07 g, 0.75 mmol) was added to a methylene chloride solution of trimethyl aluminum (0.38 mL, 0.75 mmol, 2.0 M in hexanes) at 25°C under nitrogen. After gas evolution had ceased (approx. 30 minutes), ethyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate (Example 8) (0.25 g, 0.5 mmol) was added and the mixture stirred for 24 hours at 25°C. The reaction was quenched with dilute aqueous HCl and extracted with two portions ethyl acetate and the extracts washed with brine, dried over MgSO<sub>4</sub> and concentrated in vacuo. Recrystallization from chloroform/acetone gave N-phenyl-[4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide as a white crystalline solid

(0.18 g, 68% yield). Elemental analysis for  $C_{25}H_{19}N_3F_4SO_3$  Calc'd: C, 58.02, H, 3.70, N, 8.12, S, 6.20. Found: C, 57.48, H, 3.78, N, 8.03, S, 6.46.

5


## Example 10



10                   **[4-(4-Fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid**

To a solution of ethyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate (Example 8) (0.48 g, 1.0 mmol) in  
15   tetrahydrofuran (THF) (10 mL) was added 1.5 mL of 1N aqueous lithium hydroxide at 25°C under nitrogen and the mixture stirred for 24 hours at 25°C. The reaction mixture was extracted with two portions diethyl ether and  
20   the aqueous layer was acidified with dilute aqueous HCl. This was extracted with two portions ethyl acetate which was washed with brine, dried over  $MgSO_4$  and concentrated in vacuo. Recrystallization from chloroform/acetone gave  
25   [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid as a white crystalline solid (0.41 g, 93%). Elemental analysis for  $C_{19}H_{14}N_2F_4SO_4$  Calc'd: C, 51.58, H, 3.19, N, 6.33. Found: C, 51.18, H, 3.23, N, 6.19.

## Example 11




5                    **[4-(4-Fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide**

To a solution of [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid (Example 10) (0.24 g, 0.54 mmol) in THF (6 mL) was added 0.10 g of 1,1'-carbonyldiimidazole at 25°C under nitrogen. After gas evolution had ceased (approx. 30 minutes), 6 mL conc. ammonium hydroxide was added and the mixture stirred at 25°C for 18 hours. The reaction mixture was diluted with water, extracted with two portions ethyl acetate and the organic layer washed successively with dilute aqueous HCl and brine, dried over MgSO<sub>4</sub> and concentrated in vacuo. Recrystallization from chloroform/acetone gave [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide as a white crystalline solid (0.15 g, 34%). Elemental analysis for C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>F<sub>4</sub>SO<sub>3</sub>

25    Calc'd: C, 51.70, H, 3.42, N, 9.52. Found: C, 51.46, H, 3.35, N, 9.39.


## Example 12



5                   4-(4-Fluorophenyl)-3-[4-(  
                  (methylsulfonyl)phenyl]-1-[2-(1H-pyrrolidin-1-  
                  yl)ethyl]-5-(trifluoromethyl)-1H-pyrazole

                  4-(4-Fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-  
10 5-(trifluoromethyl)-1H-pyrazole (Example 1, Step 3)  
                  (0.84 g, 2.2 mmol) was added to N-(2-  
                  chloroethyl)pyrrolidine hydrochloride (0.51 g, 3 mmol)  
                  and tetrabutylammonium iodide (0.1 g) and were stirred  
                  vigorously in 10 mL dry DMF with finely powdered  
15 potassium carbonate (0.69 g, 5 mmol) under nitrogen at  
                  60°C for 18 hours. The mixture was cooled, diluted  
                  with ethyl acetate and filtered to remove solids. The  
                  organic filtrate was washed successively with two  
                  portions of water followed by brine, dried over MgSO<sub>4</sub>  
20 and concentrated in vacuo. The desired isomer was  
                  isolated by chromatography on silica gel using 5:95:1  
                  acetone/toluene/NH<sub>4</sub>OH as the eluant, to give 4-(4-  
                  fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-[2-(1H-  
                  pyrrolidin-1-yl)ethyl]-5-(trifluoromethyl)-1H-pyrazole  
25 as white crystals (0.55 g, 52%): mp 134-135°C.  
                  Elemental analysis for C<sub>23</sub>H<sub>23</sub>N<sub>3</sub>F<sub>4</sub>SO<sub>2</sub> Calc'd: C, 57.37,  
                  H, 4.82, N, 8.73, S, 6.66. Found: C, 57.41, H,  
                  4.77, N, 8.72, S, 6.83.

## Example 13



5                    **[4-(4-Fluorophenyl)-3-[4-(methanesulfonyl)phenyl]-1H-pyrazol-1-yl]acetic acid**


10    Step 1: Preparation of ethyl [4-(4-fluorophenyl)-3-[4-(methanesulfonyl)phenyl]-1H-pyrazol-1-yl]acetate

4-(4-Fluorophenyl)-3-[4-(methanesulfonyl)phenyl]-1H-pyrazole (Example 7, Step 3) (1.26g, 4.0 mmol) and ethyl bromoacetate (0.89 g, 5.3 mmol) were stirred vigorously in 12 mL dry DMF with finely powdered potassium carbonate (1.10 g, 8 mmol) at 25°C under nitrogen for 3 hours. The mixture was diluted with ethyl acetate and filtered to remove solids. The organic filtrate was washed successively with two portions of water followed by brine, dried over MgSO<sub>4</sub> and concentrated in vacuo. The desired 1-alkyl isomer was isolated by recrystallization from ethyl acetate-hexane-acetone to give ethyl [4-(4-fluorophenyl)-3-[4-(methanesulfonyl)phenyl]-1H-pyrazol-1-yl]acetate as white crystals (1.11 g, 69%): mp 116-118°C. Elemental analysis for C<sub>20</sub>H<sub>19</sub>N<sub>2</sub>FSO<sub>4</sub> Calc'd: C, 59.69, H, 4.76, N, 6.96, S, 7.97. Found: C, 59.68, H, 5.04, N, 6.52, S, 7.38.

30    Step 2: Preparation of [4-(4-fluorophenyl)-3-[4-(methanesulfonyl)phenyl]-1H-pyrazol-1-yl]acetic acid

To a solution of ethyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetate from Step 1 (1.05 g, 2.6 mmol) in THF (20 mL) was added 3.0 mL of aqueous 1N lithium hydroxide at 25°C under nitrogen and the mixture stirred at 25°C for 24 hours. The mixture was acidified with 2N HCl, extracted with two portions ethyl acetate and the organic layer separated, washed with brine, dried over MgSO<sub>4</sub> and concentrated in vacuo. Chromatographic purification on silica gel using 20% ethanol/79% chloroform/1% acetic acid as the eluant gave [4-(4-Fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetic acid as a white solid (0.58 g, 60%). Elemental analysis for C<sub>18</sub>H<sub>15</sub>N<sub>2</sub>FSO<sub>4</sub>+0.8 CH<sub>3</sub>CO<sub>2</sub>H Calc'd: C, 55.73, H, 4.34, N, 6.63, S, 7.59. Found: C, 55.72, H, 4.35, N, 6.74, S, 7.72.

## Example 14




**4-[1-Ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide**

25

1-Ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (0.45 g, 1.0 mmol) was dissolved in 5 mL dry THF under nitrogen and treated with 0.9 mL of a 1.0 M solution of n-butyl magnesium chloride in THF at 0°C for 10 minutes and warmed to 25°C for 30 minutes. A

solution of triethylborane in THF (2.5 mL, 1.0 M) was added and the mixture was stirred at 25°C for 2 hours and at reflux for 24 hours. After cooling to 25°C, a mixture of water (1.2 mL), sodium acetate (0.90 g) and hydroxylamine-O-sulfonic acid (0.62 g) was added and the reaction stirred at 25°C for 18 hours. The mixture was partitioned between water and ethyl acetate, and the organic layer washed successively with water and brine, dried over MgSO<sub>4</sub> and concentrated in vacuo. Chromatographic purification on silica gel eluting with methyl t-butyl ether/toluene (5/95) gave 4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl] benzenesulfonamide as a white solid (0.25 g, 62% yield). Elemental analysis for C<sub>18</sub>H<sub>15</sub>N<sub>3</sub>F<sub>4</sub>SO<sub>2</sub> Calc'd: C, 52.30, H, 3.66, N, 10.16, S, 7.76. Found: C, 52.36, H, 3.72, N, 9.98, S, 7.90.

## Example 15



1-Allyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole

Reaction of 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (Example 1, Step 3) (0.1 g) with 0.08 g of potassium carbonate and 2.0 g of allyl bromide in 5 mL

of DMF gave a crude mixture of 1-allyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)pyrazole and 1-allyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole. HPLC purification with 50% ethyl acetate-hexane and recrystallization from ether-hexane gave 1-allyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (45 mg, 41%): mp 115.5-119°C.

#### BIOLOGICAL EVALUATION

##### Rat Carrageenan Foot Pad Edema Test

The carrageenan foot edema test was performed with materials, reagents and procedures essentially as described by Winter, et al., (Proc. Soc. Exp. Biol. Med., **111**, 544 (1962)). Male Sprague-Dawley rats were selected in each group so that the average body weight was as close as possible. Rats were fasted with free access to water for over sixteen hours prior to the test. The rats were dosed orally (1 mL) with compounds suspended in vehicle containing 0.5% methylcellulose and 0.025% surfactant, or with vehicle alone. One hour later a subplantar injection of 0.1 mL of 1% solution of carrageenan/sterile 0.9% saline was administered and the volume of the injected foot was measured with a displacement plethysmometer connected to a pressure transducer with a digital indicator. Three hours after the injection of the carrageenan, the volume of the foot was again measured. The average foot swelling in a group of drug-treated animals was compared with that of a group of placebo-treated animals and the percentage inhibition of edema was determined (Otterness and Bliven, Laboratory Models for Testing NSAIDs, in Non-steroidal Anti-Inflammatory Drugs, (J. Lombardino, ed. 1985)). The % inhibition shows the % decrease from



control paw volume determined in this procedure and the data for selected compounds in this invention are summarized in Table 1.

#### 5 Rat Carrageenan-induced Analgesia Test

The analgesia test using rat carrageenan was performed with materials, reagents and procedures essentially as described by Hargreaves, et al., (Pain, 10 32, 77 (1988)). Male Sprague-Dawley rats were treated as previously described for the Carrageenan Foot Pad Edema test. Three hours after the injection of the carrageenan, the rats were placed in a special plexiglass container with a transparent floor having a 15 high intensity lamp as a radiant heat source, positionable under the floor. After an initial twenty minute period, thermal stimulation was begun on either the injected foot or on the contralateral uninjected foot. A photoelectric cell turned off the lamp and 20 timer when light was interrupted by paw withdrawal. The time until the rat withdraws its foot was then measured. The withdrawal latency in seconds was determined for the control and drug-treated groups, and percent inhibition of the hyperalgesic foot 25 withdrawal determined. Results are shown in Table I.

TABLE I.

RAT PAW EDEMA		
ANALGESIA		
30	% Inhibition	% Inhibition
	@ 20mg/kg body weight	@ 20mg/kg body weight
Example		
	1	39
		22

#### 35 Evaluation of COX I and COX II activity *in vitro*

The compounds of this invention exhibited inhibition *in vitro* of COX II. The COX II inhibition activity of the compounds of this invention

illustrated in the Examples was determined by the following methods.

a. Preparation of recombinant COX baculoviruses

5

A 2.0 kb fragment containing the coding region of either human or murine COX-I or human or murine COX-II was cloned into a BamHI site of the baculovirus transfer vector pVL1393 (Invitrogen) to generate the baculovirus transfer vectors for COX-I and COX-II in a manner similar to the method of D.R. O'Reilly et al (*Baculovirus Expression Vectors: A Laboratory Manual* (1992)). Recombinant baculoviruses were isolated by transfecting 4 µg of baculovirus transfer vector DNA into SF9 insect cells (2x10<sup>8</sup>) along with 200 ng of linearized baculovirus plasmid DNA by the calcium phosphate method. See M.D. Summers and G.E. Smith, *A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures*, Texas Agric. Exp. Station Bull. 1555 (1987). Recombinant viruses were purified by three rounds of plaque purification and high titer (10<sup>7</sup> - 10<sup>8</sup> pfu/ml) stocks of virus were prepared. For large scale production, SF9 insect cells were infected in 10 liter fermentors (0.5 x 10<sup>6</sup>/ml) with the recombinant baculovirus stock such that the multiplicity of infection was 0.1. After 72 hours the cells were centrifuged and the cell pellet homogenized in Tris/Sucrose (50 mM: 25%, pH 8.0) containing 1% 3-[(3-cholamidopropyl)dimethylammonio] -1-propanesulfonate (CHAPS). The homogenate was centrifuged at 10,000xG for 30 minutes, and the resultant supernatant was stored at -80°C before being assayed for COX activity.

35

b. Assay for COX I and COX II activity:

COX activity was assayed as PGE<sub>2</sub> formed/µg protein/time using an ELISA to detect the

prostaglandin released. CHAPS-solubilized insect cell membranes containing the appropriate COX enzyme were incubated in a potassium phosphate buffer (50 mM, pH 8.0) containing epinephrine, phenol, and heme with the addition of arachidonic acid (10  $\mu$ M). Compounds were pre-incubated with the enzyme for 10-20 minutes prior to the addition of arachidonic acid. Any reaction between the arachidonic acid and the enzyme was stopped after ten minutes at 37°C/room temperature by transferring 40  $\mu$ l of reaction mix into 160  $\mu$ l ELISA buffer and 25  $\mu$ M indomethacin. The PGE<sub>2</sub> formed was measured by standard ELISA technology (Cayman Chemical). Results are shown in Table II.

TABLE II.

		Human COX I	Human COX II
		IC <sub>50</sub> $\mu$ M	IC <sub>50</sub> $\mu$ M
Example			
20	1	>10	<.1
	2	>10	<.1
	7	>100	.5
	8	>100	.4
	9	>100	.6
25	10	>100	23
	11	>100	11
	12	>100	3
	13	>100	76
	14	1.3	<.1
30	15	>10	<.1

Biological paradigms for testing the cytokine-inhibiting activity of these compounds are found in WO95/13067, published 18 May 1995.

Also embraced within this invention is a class of pharmaceutical compositions comprising the active compounds of this combination therapy in association

with one or more non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The active compounds  
5 of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The active compounds and composition may, for example, be  
10 administered orally, intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically.

For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical  
15 composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. The active ingredient may also be administered by injection as a composition wherein, for example,  
20 saline, dextrose or water may be used as a suitable carrier.

The amount of therapeutically active compounds that are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions  
25 of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound employed, and thus may vary widely. The pharmaceutical  
30 compositions may contain active ingredients in the range of about 0.1 to 2000 mg, preferably in the range of about 0.5 to 500 mg and most preferably between about 1 and 100 mg. A daily dose of about 0.01 to 100 mg/kg body weight, preferably between about 0.5 and about 20 mg/kg body  
35 weight and most preferably between about 0.1 to 10 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day.

In the case of psoriasis and other skin conditions, it may be preferable to apply a topical preparation of compounds of this invention to the affected area two to four times a day.

5 For inflammations of the eye or other external tissues, e.g., mouth and skin, the formulations are preferably applied as a topical ointment or cream, or as a suppository, containing the active ingredients in a total amount of, for example, 0.075 to 30% w/w,  
10 preferably 0.2 to 20% w/w and most preferably 0.4 to 15% w/w. When formulated in an ointment, the active ingredients may be employed with either paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-  
15 water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may  
20 desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs. The compounds of this invention can  
25 also be administered by a transdermal device. Preferably topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the reservoir or  
30 microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In  
35 the case of microcapsules, the encapsulating agent may also function as the membrane.

The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one  
5 emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without  
10 stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the  
15 formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate, among others.

The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic  
20 properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid  
25 leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-  
30 ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be  
35 used.

Formulations suitable for topical administration to the eye also include eye drops wherein the active


ingredients are dissolved or suspended in suitable carrier, especially an aqueous solvent for the active ingredients. The antiinflammatory active ingredients are preferably present in such formulations in a  
5 concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w.

For therapeutic purposes, the active compounds of this combination invention are ordinarily combined with one or more adjuvants appropriate to the indicated route  
10 of administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric  
15 and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active  
20 compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or  
25 granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol,  
30 sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Although this invention has been described with respect to specific embodiments, the details of these  
35 embodiments are not to be construed as limitations.

What is claimed is:

1. A compound of Formula I



5

wherein R<sup>1</sup> is selected from hydrido, alkyl, alkenyl, alkynyl, haloalkyl, aralkyl, heterocyclicalkyl, heteroaralkyl, hydroxyalkyl, alkoxyalkyl, cyanoalkyl, aminoalkyl, alkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, alkylaminocarbonylalkyl, N-hydroxyaminocarbonylalkyl, N-hydroxy-N-alkyl-aminocarbonylalkyl, arylaminocarbonylalkyl and aminocarbonylalkyl;

15 wherein R<sup>2</sup> and R<sup>3</sup> are independently selected from aryl, cycloalkyl, cycloalkenyl and heterocyclo, wherein R<sup>2</sup> and R<sup>3</sup> are optionally substituted at a substitutable position with one or more radicals independently selected from alkylsulfonyl, aminosulfonyl, haloalkylsulfonyl, halo, alkylthio, alkylsulfinyl, alkyl, cyano, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, haloalkyl, hydroxyl, alkoxy, hydroxyalkyl, alkoxyalkyl, haloalkoxy, amino, alkylamino, arylamino, heterocyclo and nitro; and

25 wherein R<sup>4</sup> is selected from hydrido, alkyl, haloalkyl, cyano, acyl, alkoxy, carboxyl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aminocarbonyl, heteroaryl, alkylaminocarbonyl, arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, aminocarbonylalkyl, hydroxyalkyl and aralkoxyalkyl;

30 provided one of R<sup>2</sup> and R<sup>3</sup> are substituted with a radical selected from alkylsulfonyl, aminosulfonyl, and haloalkylsulfonyl;

35



or a pharmaceutically-acceptable salt thereof.

2. Compound of Claim 1 wherein R<sup>1</sup> is selected from hydrido, lower alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, lower aralkyl, lower heterocyclicalkyl, lower heteroaralkyl, lower hydroxyalkyl, lower alkoxyalkyl, lower cyanoalkyl, lower aminoalkyl, lower alkylaminoalkyl, lower carboxyalkyl, lower alkoxycarbonylalkyl, lower alkylaminocarbonylalkyl, lower N-hydroxyaminocarbonylalkyl, lower N-hydroxy-N-alkylaminocarbonylalkyl, lower arylaminocarbonylalkyl and lower aminocarbonylalkyl; wherein R<sup>2</sup> and R<sup>3</sup> are independently selected from aryl selected from phenyl, naphthyl and biphenyl, lower cycloalkyl, lower cycloalkenyl and heterocyclo, wherein R<sup>2</sup> and R<sup>3</sup> are optionally substituted at a substitutable position with one or more radicals independently selected from lower alkylsulfonyl, aminosulfonyl, halo, lower haloalkylsulfonyl, lower alkylthio, lower alkyl, lower alkylsulfinyl, cyano, carboxyl, lower alkoxycarbonyl, aminocarbonyl, lower alkylaminocarbonyl, phenylaminocarbonyl, lower N-alkyl-N-arylaminocarbonyl, lower haloalkyl, hydroxyl, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, heterocyclo and nitro; and wherein R<sup>4</sup> is selected from hydrido, lower alkyl, lower haloalkyl, cyano, acyl, lower alkoxy, carboxyl, lower carboxyalkyl, lower alkoxycarbonyl, lower alkoxycarbonylalkyl, lower aralkoxycarbonylalkyl, aminocarbonyl, heteroaryl, lower alkylaminocarbonyl, lower arylaminocarbonyl, lower N-alkyl-N-arylaminocarbonyl, lower aminocarbonylalkyl, lower hydroxyalkyl and lower aralkoxyalkyl; or a pharmaceutically-acceptable salt thereof.

3. Compound of Claim 2 wherein R<sup>1</sup> is selected from methyl, ethyl, isopropyl, tert-butyl, isobutyl,

fluoromethyl, difluoromethyl, trifluoromethyl,  
chloromethyl, dichloromethyl, trichloromethyl,  
pentafluoroethyl, heptafluoropropyl,  
difluorochloromethyl, dichlorofluoromethyl,  
5 difluoroethyl, difluoropropyl, dichloroethyl,  
dichloropropyl, ethylenyl, propylenyl, butenyl,  
pentenyl, isopropylenyl, isobutylenyl, propargyl,  
benzyl, phenylethyl, phenylpropyl, morpholinomethyl,  
pyrrolidinylmethyl, piperazinylmethyl,  
10 piperidinylmethyl, pyridylmethyl, thienylmethyl,  
hydroxymethyl, hydroxyethyl, methoxymethyl,  
ethoxymethyl, cyanomethyl, aminomethyl,  
methylaminomethyl, formyl, acetyl, propanyl, butanyl,  
methoxycarbonylmethyl, ethoxycarbonylethyl, N-  
15 methylaminocarbonylmethyl, N,N-  
dimethylaminocarbonylmethyl, N-  
hydroxyaminocarbonylmethyl, N-hydroxy-N-  
methylaminocarbonylmethyl, N-phenylaminocarbonylmethyl  
and aminocarbonylmethyl; wherein R<sup>2</sup> and R<sup>3</sup> are  
20 independently selected from phenyl, naphthyl, biphenyl,  
cyclohexyl, cyclopentyl, cycloheptyl, 1-cyclohexenyl,  
2-cyclohexenyl, 3-cyclohexenyl, 4-cyclohexenyl, 4-  
methylcyclohex-4-en-1-yl, 1-cyclopentenyl, pyridyl,  
thienyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl,  
25 isoquinolinyl, imidazolyl, benzimidazolyl, furyl and  
pyrazinyl, wherein R<sup>2</sup> and R<sup>3</sup> are optionally substituted  
at a substitutable position with one or more radicals  
independently selected from methylsulfonyl,  
aminosulfonyl, fluoro, chloro, bromo, methylthio,  
30 methylsulfinyl, cyano, methyl, ethyl, isopropyl, tert-  
butyl, isobutyl, carboxyl, methoxycarbonyl,  
ethoxycarbonyl, isopropoxycarbonyl, tert-  
butoxycarbonyl, propoxycarbonyl, butoxycarbonyl,  
isobutoxycarbonyl, pentoxycarbonyl, aminocarbonyl, N-  
35 methylaminocarbonyl, N-ethylaminocarbonyl, N-  
isopropylaminocarbonyl, N-propylaminocarbonyl, N-  
butylaminocarbonyl, N-isobutylaminocarbonyl, N-tert-  
butylaminocarbonyl, N-pentylaminocarbonyl, N,N-

- dimethylaminocarbonyl, N-methyl-N-ethylaminocarbonyl, N-phenylaminocarbonyl, N-(3-fluorophenyl)aminocarbonyl, N-(4-methylphenyl)aminocarbonyl, N-(3-chlorophenyl)aminocarbonyl, N-(4-methoxyphenyl)aminocarbonyl, N-methyl-N-phenylaminocarbonyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxyl, methoxy, methylenedioxy, ethoxy, propoxy, n-butoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxymethyl, amino, N-methylamino, N,N-dimethylamino, N-methyl-N-phenylamino, N-phenylamino, morpholino, pyrrolidinyl, piperazinyl and piperidinyl and nitro; and wherein R<sup>4</sup> is selected from hydrido, methyl, ethyl, isopropyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, n-butoxy, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyano, formyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, propoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, pentoxycarbonyl, methoxycarbonylalkyl, benzyloxycarbonylmethyl, aminocarbonyl, N-methylaminocarbonyl, N-ethylaminocarbonyl, N-isopropylaminocarbonyl, N-propylaminocarbonyl, N-butylaminocarbonyl, N-isobutylaminocarbonyl, N-tert-butylaminocarbonyl, N-pentylaminocarbonyl, N,N-dimethylaminocarbonyl, N-methyl-N-ethylaminocarbonyl, N-phenylaminocarbonyl, N-(3-fluorophenyl)aminocarbonyl, N-(4-methylphenyl)aminocarbonyl, N-(3-chlorophenyl)aminocarbonyl, N-(4-methoxyphenyl)aminocarbonyl, N-methyl-N-

phenylaminocarbonyl, aminocarbonylmethyl, hydroxypropyl, hydroxymethyl, hydroxyethyl, butanyl, acetyl, propanyl and benzyloxymethyl; or a pharmaceutically-acceptable salt thereof.

5

4. Compound of Claim 3 selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of

- 10 4-(3-pyridyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-(4-pyridyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;  
5-(difluoromethyl)-1-methyl-4-(4-pyridyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
15 1,5-dimethyl-4-(4-pyridyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
5-(hydroxymethyl)-1-methyl-4-(4-pyridyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole;  
20 methyl [1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
[1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-phenyl-[1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
25 N-methyl-[1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N,N-dimethyl-[1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
30 N-methyl-N-phenyl-[1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1H-pyrazole;  
35 1-methyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-ethyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;

- 1-ethyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyrimidinyl)-  
5-(trifluoromethyl)-1H-pyrazole;  
1-ethyl-3-[4-(methylsulfonyl)phenyl]-4-(quinolyl)-5-  
(trifluoromethyl)-1H-pyrazole;  
5 1-benzyl-3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-  
(trifluoromethyl)-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1-(3-  
propenyl)-5-(trifluoromethyl)-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1-(3-  
propynyl)-5-(trifluoromethyl)-1H-pyrazole;  
10 1-cyanomethyl-3-[4-(methylsulfonyl)phenyl]-4-(4-  
pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
ethyl [3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-  
(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
15 methyl [3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-  
(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
N-phenyl [3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-  
(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
[3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-  
(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;  
20 [3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-5-  
(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
1-(3-hydroxypropyl)-3-[4-(methylsulfonyl)phenyl]-4-(4-  
pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
25 3-[4-(methylsulfonyl)phenyl]-4-(4-pyridyl)-1-[2-(2-  
pyridyl)ethyl]-5-(trifluoromethyl)-1H-pyrazole;  
3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-4-(4-  
pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-[2-(dimethylamino)ethyl]-3-[4-  
30 (methylsulfonyl)phenyl]-4-(4-pyridyl)-5-  
(trifluoromethyl)-1H-pyrazole;  
N-hydroxy-N-methyl-[3-[4-(methylsulfonyl)phenyl]-4-  
(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-  
yl]acetamide;  
35 1-methyl-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-  
(trifluoromethyl)-1H-pyrazole;  
1-ethyl-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-  
(trifluoromethyl)-1H-pyrazole;

- 1-benzyl-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazole;  
5 4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-cyanomethyl-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
ethyl [4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
10 methyl [4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
N-phenyl [4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
15 [4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;  
[4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
1-(3-hydroxypropyl)-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
20 4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-1-[2-(2-pyridyl)ethyl]-5-(trifluoromethyl)-1H-pyrazole;  
4-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
25 1-[2-(dimethylamino)ethyl]-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
N-hydroxy-N-methyl-[4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
30 4-[4-(2-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
35 4-[5-(difluoromethyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1,5-dimethyl-4-(4-pyridyl)-1H-pyrazol-3-

- yl]benzenesulfonamide;  
4-[5-(hydroxymethyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
methyl [3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
5 ethyl [3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
isopropyl [3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
10 tert-butyl [3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
benzyl [3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
[3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
15 N-methyl-[3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-phenyl-[3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
20 N,N-dimethyl-[3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-methyl-N-phenyl-[3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
[3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carboxylic acid;  
25 [3-(4-aminosulfonylphenyl)-1-methyl-4-(4-pyridyl)-1H-pyrazol-5-yl]carbonitrile;  
4-[1-methyl-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;  
30 4-[1-methyl-3-(4-pyridyl)-1H-pyrazol-4-yl]benzenesulfonamide;  
4-[5-(difluoromethyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-4-yl]benzenesulfonamide;  
4-[1,5-dimethyl-3-(4-pyridyl)-1H-pyrazol-4-yl]benzenesulfonamide;  
35 4-[5-(hydroxymethyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-4-yl]benzenesulfonamide;

- methyl [4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
ethyl [4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
5 isopropyl [4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
tert-butyl [4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
benzyl [4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
10 [4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-methyl-[4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
15 N-phenyl-[4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N,N-dimethyl-[4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-methyl-N-phenyl-[4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
20 [4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylic acid;  
[4-(4-aminosulfonylphenyl)-1-methyl-3-(4-pyridyl)-1H-pyrazol-5-yl]carbonitrile;  
25 1-methyl-4-(methanesulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazole;  
1-methyl-3-(4-pyridyl)-4-[4-(methanesulfonyl)phenyl]-1H-pyrazole;  
30 5-(difluoromethyl)-1-methyl-3-(4-pyridyl)-4-[4-(methanesulfonyl)phenyl]-1H-pyrazole;  
1,5-dimethyl-3-(4-pyridyl)-4-[4-(methanesulfonyl)phenyl]-1H-pyrazole;  
5-(hydroxymethyl)-1-methyl-3-(4-pyridyl)-4-[4-(methanesulfonyl)phenyl]-1H-pyrazole;  
35 methyl [1-methyl-4-[4-(methanesulfonyl)phenyl]-3-(4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
ethyl [1-methyl-4-[4-(methanesulfonyl)phenyl]-3-(4-




- pyridyl)-1H-pyrazol-5-yl]carboxylate;  
isopropyl [1-methyl-4-[4-(methylsulfonyl)phenyl]-3-(4-  
pyridyl)-1H-pyrazol-5-yl]carboxylate;  
tert-butyl [1-methyl-4-[4-(methylsulfonyl)phenyl]-3-  
5 (4-pyridyl)-1H-pyrazol-5-yl]carboxylate;  
benzyl [1-methyl-4-[4-(methylsulfonyl)phenyl]-3-(4-  
pyridyl)-1H-pyrazol-5-yl]carboxylate;  
[1-methyl-4-[4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-  
1H-pyrazol-5-yl]carboxylic acid;  
10 [4-[1-methyl-4-(methylsulfonyl)phenyl]-3-(4-pyridyl)-  
1H-pyrazol-5-yl]carboxamide;  
N-phenyl-[1-methyl-4-[4-(methylsulfonyl)phenyl]-3-(4-  
pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-methyl-[1-methyl-4-[4-(methylsulfonyl)phenyl]-3-(4-  
15 pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N,N-dimethyl-[1-methyl-4-[4-(methylsulfonyl)phenyl]-3-  
(4-pyridyl)-1H-pyrazol-5-yl]carboxamide;  
N-methyl-N-phenyl-[1-methyl-4-[4-  
(methylsulfonyl)phenyl]-3-(4-pyridyl)-1H-pyrazol-  
20 5-yl]carboxamide;  
4-[1-ethyl-4-(4-pyridyl)-5-(trifluoromethyl)-1H-  
pyrazol-3-yl]benzenesulfonamide;  
4-[1-benzyl-4-(4-pyridyl)-5-(trifluoromethyl)-1H-  
pyrazol-3-yl]benzenesulfonamide;  
25 4-[4-(4-pyridyl)-1-(3-propenyl)-5-(trifluoromethyl)-  
1H-pyrazol-3-yl]benzenesulfonamide;  
4-[4-(4-pyridyl)-1-(3-propynyl)-5-(trifluoromethyl)-  
1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-cyanomethyl-4-(4-pyridyl)-5-(trifluoromethyl)-1H-  
30 pyrazol-3-yl]benzenesulfonamide;  
ethyl [3-[4-(aminosulfonyl)phenyl]-4-(4-pyridyl)-5-  
(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
methyl [3-[4-(aminosulfonyl)phenyl]-4-(4-pyridyl)-5-  
(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
35 N-phenyl-[3-[4-(aminosulfonyl)phenyl]-4-(4-pyridyl)-5-  
(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
[3-[4-(aminosulfonyl)phenyl]-4-(4-pyridyl)-5-  
(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;

- [3-[4-(aminosulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
4-[1-[2-(2-pyridyl)ethyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
5 4-[1-(2-phenylethyl)-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
N-hydroxy-N-methyl-[3-(4-(aminosulfonyl)phenyl)-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
10 4-[1-(3-hydroxypropyl)-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
15 4-[1-[2-(dimethylamino)ethyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;  
4-[1-ethyl-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;  
20 4-[1-benzyl-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;  
4-[3-(4-pyridyl)-1-(3-propenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;  
25 4-[3-(4-pyridyl)-1-(3-propynyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;  
4-[1-cyanomethyl-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;  
ethyl [4-[4-(aminosulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
30 methyl [4-[4-(aminosulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;  
N-phenyl-[4-[4-(aminosulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;  
35 [4-[4-(aminosulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;  
[4-[4-(aminosulfonyl)phenyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;

- 4-[1-[2-(2-pyridyl)ethyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;
- 5 4-[1-(2-phenylethyl)-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;
- N-hydroxy-N-methyl-[3-(4-aminosulfonyl)phenyl]-4-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;
- 10 4-[1-(3-hydroxypropyl)-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;
- 4-[1-[2-(dimethylamino)ethyl]-3-(4-pyridyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]benzenesulfonamide;
- 15
- 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-5-(trifluoromethyl)-1H-pyrazole;
- 1-cyanomethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 20
- 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-propargyl)-5-(trifluoromethyl)-1H-pyrazole;
- 1-benzyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 25
- 4-(4-fluorophenyl)-1-methyl-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 30 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-5-(trifluoromethyl)-1H-pyrazole;
- 1-ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 35 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-[2-(1H-pyrrolidin-1-yl)ethyl]-5-(trifluoromethyl)-1H-pyrazole;

- ethyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;
- N-phenyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;
- 5 [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid;
- [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;
- 10 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-allyl-5-trifluoromethyl-1H-pyrazole;
- 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]acetic acid; and
- 15 4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide.

5. A compound of Formula II



20

- wherein R<sup>1</sup> is selected from alkyl, aralkyl, alkynyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl, arylaminocarbonylalkyl, heterocyclicalkyl, and
- 25 alkoxycarbonylalkyl;

- wherein R<sup>3</sup> is aryl optionally substituted at a substitutable position with one or more radicals independently selected from halo, alkylthio, alkylsulfinyl, alkyl, cyano, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, haloalkyl, hydroxyl, alkoxy, hydroxyalkyl, alkoxyalkyl, haloalkoxy, amino, alkylamino, arylamino, heterocyclo and nitro;
- 30

wherein R<sup>4</sup> is haloalkyl; and  
wherein R<sup>5</sup> is selected from alkyl and amino;  
or a pharmaceutically-acceptable salt thereof.


5           6. Compound of Claim 5 wherein R<sup>1</sup> is selected  
from lower alkyl, lower aralkyl, lower alkynyl, lower  
cyanoalkyl, lower carboxyalkyl, lower  
aminocarbonylalkyl, lower arylaminocarbonylalkyl, lower  
heterocyclicalkyl and lower alkoxy carbonylalkyl;  
10       wherein R<sup>3</sup> is aryl selected from phenyl, naphthyl and  
biphenyl, wherein said aryl radical is optionally  
substituted at a substitutable position with one or  
more radicals independently selected from halo, lower  
alkylthio, lower alkyl, carboxyl, lower haloalkyl,  
15       lower alkoxy carbonyl, aminocarbonyl, lower alkoxy,  
lower alkylaminocarbonyl, hydroxyl, amino, and lower  
alkylamino; wherein R<sup>4</sup> is lower haloalkyl; and wherein  
R<sup>5</sup> is selected from lower alkyl and amino; or a  
pharmaceutically-acceptable salt thereof.

20

          7. Compound of Claim 6 wherein R<sup>1</sup> is selected  
from methyl, ethyl, propyl, isopropyl, butyl, isobutyl,  
tert-butyl, benzyl, phenylethyl, phenylpropyl,  
propargyl, cyanomethyl, cyanoethyl, acetyl, propargyl,  
25       butanyl, morpholinomethyl, pyrrolidinylmethyl,  
piperazinylmethyl, piperidinylmethyl,  
tetrahydrofurylmethyl, acetamidyl, phenylacetamidyl,  
methoxycarbonylmethyl, ethoxycarbonylmethyl,  
isopropoxycarbonylmethyl, tert-butoxycarbonylmethyl,  
30       propoxycarbonylethyl, butoxycarbonylethyl,  
isobutoxycarbonylmethyl, and pentoxycarbonylmethyl;  
wherein R<sup>3</sup> is phenyl optionally substituted at a  
substitutable position with one or more radicals  
selected from fluoro, chloro, bromo, methylthio,  
35       methyl, carboxyl, trifluoromethyl, ethoxycarbonyl,  
aminocarbonyl, methoxy, methylaminocarbonyl, hydroxyl,  
amino, and N,N-dimethylamino; wherein R<sup>4</sup> is selected  
from fluoromethyl, difluoromethyl, trifluoromethyl,

chloromethyl, dichloromethyl, trichloromethyl,  
 pentafluoroethyl, heptafluoropropyl,  
 difluorochloromethyl, dichlorofluoromethyl,  
 difluoroethyl, difluoropropyl, dichloroethyl and  
 5 dichloropropyl; and wherein  $R^5$  is selected from methyl,  
 ethyl, and amino; or a pharmaceutically-acceptable  
 salt thereof.

10 8. A compound of Formula III



wherein  $R^1$  is selected from hydrido, alkyl,  
 aralkyl, alkynyl, cyanoalkyl, carboxyalkyl,  
 15 aminocarbonylalkyl, arylaminocarbonylalkyl,  
 heterocyclicalkyl, and alkoxyalkyl;  
 wherein  $R^4$  is selected from alkyl, haloalkyl,  
 cyano, acyl, alkoxy, carboxyl, carboxyalkyl,  
 alkoxyalkyl, alkoxyalkylalkyl,  
 20 aralkoxyalkylalkyl, aminocarbonyl, heteroaryl,  
 alkylaminocarbonyl, arylaminocarbonyl, N-alkyl-N-  
 arylaminocarbonyl, aminocarbonylalkyl, hydroxyalkyl and  
 aralkoxyalkyl;

wherein  $R^5$  is selected from alkyl and amino; and  
 25 wherein  $R^6$  is nitrogen-containing heteroaryl  
 optionally substituted at a substitutable position with  
 one or more substituents independently selected from  
 halo, alkyl, alkoxy, alkylthio, amino and alkylamino;  
 or a pharmaceutically-acceptable salt thereof.

30 9. Compound of Claim 8 wherein  $R^1$  is selected  
 from hydrido, lower alkyl, lower aralkyl, lower  
 alkynyl, lower cyanoalkyl, lower carboxyalkyl, lower  
 aminocarbonylalkyl, lower arylaminocarbonylalkyl, lower

heterocyclicalkyl and lower alkoxy carbonylalkyl;  
wherein R<sup>4</sup> is selected from hydrido and lower haloalkyl;  
wherein R<sup>5</sup> is selected from lower alkyl and amino; and  
wherein R<sup>6</sup> is nitrogen-containing heteroaryl optionally  
5 substituted at a substitutable position with one or  
more substituents independently selected from halo,  
lower alkyl, lower alkoxy, lower alkylthio, amino and  
lower alkylamino; or a pharmaceutically-acceptable salt  
thereof.

10

10. Compound of Claim 9 wherein R<sup>1</sup> is selected  
from hydrido, methyl, ethyl, propyl, isopropyl, butyl,  
isobutyl, tert-butyl, benzyl, phenylethyl,  
phenylpropyl, propargyl, cyanomethyl, cyanoethyl,  
15 acetyl, propanyl, butanyl, morpholinomethyl,  
pyrrolidinylmethyl, piperazinylmethyl,  
piperidinylmethyl, tetrahydrofurylmethyl, acetamidyl,  
phenylacetamidyl, methoxycarbonylmethyl,  
ethoxycarbonylmethyl, isopropoxycarbonylmethyl, tert-  
20 butoxycarbonylmethyl, propoxycarbonylethyl,  
butoxycarbonylethyl, isobutoxycarbonylmethyl, and  
pentoxycarbonylmethyl; wherein R<sup>4</sup> is selected from  
hydrido, fluoromethyl, difluoromethyl, trifluoromethyl,  
chloromethyl, dichloromethyl, trichloromethyl,  
25 pentafluoroethyl, heptafluoropropyl,  
difluorochloromethyl, dichlorofluoromethyl,  
difluoroethyl, difluoropropyl, dichloroethyl and  
dichloropropyl; wherein R<sup>5</sup> is selected from methyl,  
ethyl, and amino; and wherein R<sup>6</sup> is selected from  
30 pyridyl, thienyl, thiazolyl, oxazolyl, pyrimidinyl,  
quinolyl, isoquinolinyl, imidazolyl, and  
benzimidazolyl, wherein R<sup>6</sup> is optionally substituted at  
a substitutable position with one or more substituents  
independently selected from fluoro, chloro, bromo,  
35 methyl, ethyl, isopropyl, tert-butyl, isobutyl,  
methoxy, ethoxy, isopropoxy, tert-butoxy, propoxy,  
butoxy, isobutoxy, pentoxy, methylthio, amino, N-

methyamino and N,N-dimethylamino; or a pharmaceutically-acceptable salt thereof.

11. A pharmaceutical composition comprising a  
5 therapeutically-effective amount of a compound, said compound selected from a family of compounds of Claim 1; or a pharmaceutically-acceptable salt thereof.

12. A pharmaceutical composition comprising a  
10 therapeutically-effective amount of a compound, said compound selected from a family of compounds of Claim 2; or a pharmaceutically-acceptable salt thereof.

13. A pharmaceutical composition comprising a  
15 therapeutically-effective amount of a compound, said compound selected from a family of compounds of Claim 3; or a pharmaceutically-acceptable salt thereof.

14. A pharmaceutical composition comprising a  
20 therapeutically-effective amount of a compound, said compound selected from a family of compounds of Claim 4; or a pharmaceutically-acceptable salt thereof.

15. A pharmaceutical composition comprising a  
25 therapeutically-effective amount of a compound, said compound selected from a family of compounds of Claim 5; or a pharmaceutically-acceptable salt thereof.

16. A pharmaceutical composition comprising a  
30 therapeutically-effective amount of a compound, said compound selected from a family of compounds of Claim 6; or a pharmaceutically-acceptable salt thereof.

17. A pharmaceutical composition comprising a  
35 therapeutically-effective amount of a compound, said compound selected from a family of compounds of Claim 7; or a pharmaceutically-acceptable salt thereof.



18. A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from a family of compounds of Claim 8; or a pharmaceutically-acceptable salt thereof.

5

19. A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from a family of compounds of Claim 9; or a pharmaceutically-acceptable salt thereof.

10

20. A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from a family of compounds of Claim 10; or a pharmaceutically-acceptable salt thereof.

15

21. A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising administering to the subject having such inflammation or inflammation-associated disorder, a therapeutically-effective amount of a compound of Claim 1; or a pharmaceutically-acceptable salt thereof.

20

22. A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising administering to the subject having such inflammation or inflammation-associated disorder, a therapeutically-effective amount of a compound of Claim 2; or a pharmaceutically-acceptable salt thereof.

25

23. A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising administering to the subject having such inflammation or inflammation-associated disorder, a therapeutically-effective amount of a compound of Claim 3; or a pharmaceutically-acceptable salt thereof.

30

35

24. A method of treating inflammation or an inflammation-associated disorder in a subject, said

method comprising administering to the subject having such inflammation or inflammation-associated disorder, a therapeutically-effective amount of a compound of Claim 4; or a pharmaceutically-acceptable salt thereof.

5

25. A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising administering to the subject having such inflammation or inflammation-associated disorder, a therapeutically-effective amount of a compound of Claim 5; or a pharmaceutically-acceptable salt thereof.

10

26. A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising administering to the subject having such inflammation or inflammation-associated disorder, a therapeutically-effective amount of a compound of Claim 6; or a pharmaceutically-acceptable salt thereof.

15

27. A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising administering to the subject having such inflammation or inflammation-associated disorder, a therapeutically-effective amount of a compound of Claim 7; or a pharmaceutically-acceptable salt thereof.

20

25

28. A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising administering to the subject having such inflammation or inflammation-associated disorder, a therapeutically-effective amount of a compound of Claim 8; or a pharmaceutically-acceptable salt thereof.

30

29. A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising administering to the subject having such inflammation or inflammation-associated disorder,

35

a therapeutically-effective amount of a compound of Claim 9; or a pharmaceutically-acceptable salt thereof.

30. A method of treating inflammation or an  
5 inflammation-associated disorder in a subject, said  
method comprising administering to the subject having  
such inflammation or inflammation-associated disorder,  
a therapeutically-effective amount of a compound of  
Claim 10; or a pharmaceutically-acceptable salt  
10 thereof.

31. The method of Claim 21 for use in treatment of  
inflammation.

15 32. The method of Claim 21 for use in treatment of  
an inflammation-associated disorder.

33. The method of Claim 32 wherein the  
inflammation-associated disorder is arthritis.  
20

34. The method of Claim 32 wherein the  
inflammation-associated disorder is pain.

35. The method of Claim 32 wherein the  
25 inflammation-associated disorder is fever.

# INTERNATIONAL SEARCH REPORT

In tional Application No  
PCT/US 95/08788

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07D231/12 A61K31/415

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 418 845 (FUJISAWA PHARMACEUTICAL CO., LTD.) 27 February 1991 cited in the application see page 55; claim 1 see page 31; example 11.3 see page 21, line 54 - page 22, line 12 -----	1-35
A	US,A,3 984 431 (C. GUÉREMY ET AL.) 5 October 1976 cited in the application see column 1, line 7 - line 52 see column 8 - column 9; example 1 -----	1-35

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

14 November 1995

Date of mailing of the international search report

22.11.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Fink, D

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/08788

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 21-35 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 95/08788

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0418845	27-03-91	AT-T- 126216	15-08-95
		AU-B- 637142	20-05-93
		AU-B- 6307290	18-04-91
		CN-A- 1050382	03-04-91
		DE-D- 69021472	14-09-95
		JP-A- 3141261	17-06-91
		RU-C- 2021990	30-10-94
		US-A- 5134142	28-07-92
-----			
US-A-3984431	05-10-76	GB-A- 1387306	12-03-75
		AT-B- 326649	29-12-75
		BE-A- 796465	02-07-73
		CH-A- 581117	29-10-76
		DE-A- 2312256	27-09-73
		FR-A, B 2176018	26-10-73
		JP-C- 957412	14-06-79
		JP-A- 49092067	03-09-74
		JP-B- 53037863	12-10-78
		NL-A- 7303658	18-09-73
		SE-B- 400556	03-04-78
-----			

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**